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ABSTRACT 
Obesity has been associated with hypercoagulability and increased risk of both arterial 
and venous thromboembolic events. Many different and complex changes in plasma 
coagulation factors have been described in patients with obesity. Conventional plasma 
recalcification times don’t assess the entire process in physiological and holistic manner. 
In a case-control study, the presence of hypercoagulability was evaluated in free of 
metabolic syndrome overweight and obese patients by measuring different subtypes of 
microparticles (MPs), thrombin generation, whole blood rotation thromboelastometry 
(ROTEM®) and impedance aggregometry (Multiplate®). Furthermore, the levels of MPs 
were prospectively measured in a group of 20 III degree obese patients before and after 
12 months bariatric surgery in order to investigate the effect of weight loss. 
Twenty overweight patients (body mass index [BMI] range 25–29.9 kg/m2), 20 with I 
degree (30-34.9 kg/m
2
), 20 with II degree (35–39.9 kg/m2) and 20 with III degree obesity 
(< 40 kg/m
2
) were enrolled and compared to 40 age and gender-matched normal weight 
individuals.  
Microparticles: a significant increase in median levels of all MP subtypes was observed 
in the three degrees of obese patients compared to controls. All MPs, except for 
endothelial-derived MP, which had significantly decreased at T3, all MPs subtypes had 
significantly decreased at T12. Thrombin generation: obese patients had a significantly 
shorter median lag time, higher median peak thrombin and increased median endogenous 
thrombin potential compared to controls. Thromboelastometry: in INTEM and EXTEM 
tests MCF and AUC were significantly increased in III degree obese compared with 
controls; MCF in FIBTEM was significantly higher in I, II and III degree obesity than 
controls. Impedance aggregometry: a significant difference in platelet aggregation was 
found between III degree obese subjects and healthy controls in each of the tests 
considered. 
We conclude that obesity is associated with overproduction of procoagulant MP and 
increase thrombin generation. A relationship between hypercoagulability detected by 
whole blood thromboelastometry and aggregometry and increased fat mass is shown. 
Assessment of global hemostasis tests may be helpful in the early characterization of the 
prothrombotic state in obese patients. 
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1. INTRODUCTION 
1.1. Definition of Obesity and Body Weight Categories 
The World Health Organization (WHO) defines obesity as ‘a condition of abnormal or 
excessive fat accumulation in adipose tissue, to the extent that health may be 
impaired’.[1] 
Measurement of height and weight was the initial step in the clinical assessment of 
overweight and obesity. 
The first concept used was percent of ideal body weight. Remote studies suggested that 
terms like “healthy or good weight ranges” were associated with decreased 
mortality. Afterwards, body mass index (BMI) substituted the assessment of obesity, 
calculated as body weight (in kg) divided by height (in meters) squared. The initial use of 
the index was in 1842 by Quetelet, a Belgian mathematician, who noticed that in people 
he considered to have a “normal frame” the weight was proportional to the height 
squared. 
With the help of experts from around the world who formed ‘The International Obesity 
Task Force’, in 1997 the World Health Organization (WHO) came up with the definition 
of obesity as a BMI ≥ 30 kg/m2, using data from the Third Health and Nutrition 
Examination Survey found that the optimal BMI for longevity in whites was 23–25, and 
that in blacks was 23–30 kg/m2.[2] Overweight or pre-obesity as the weight category 
encompassing the BMI range between 25 and < 30 kg/m² and obesity is defined as a BMI 
≥ 30 kg/m²; obesity in turn is subdivided into classes I, II and III (Table 1).  
 
Classification BMI kg/m
2 
 
[general cut off point] 
BMI kg/m
2 
 
[cut off point for Asian population] 
Underweight  < 18.5 < 18.5 
Normal range 18.5 - 24.9 15.5 – 22.9 
Pre-obese 25.0 – 29.9 23.0 – 27.4 
Obese class I 30.0 – 34.9 27.5 – 32.4 
Obese class II 35.0 – 39.9 32.5 – 37.4 
Obese class III ≥ 40.0 ≥37.5 
 
Table 1: The classification of weight category by BMI, adapted from WHO.[3] 
 
The definitions and classifications of body weight categories have changed over time.[4] 
BMI is widely used to indirectly assess adiposity, but over the last 30 years there have 
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been several new concepts challenging the simplistic concept that obesity can be 
diagnosed based on weight and height. 
Obesity is associated with a reduced life expectancy, largely because obese individuals 
are at an increased risk of type 2 diabetes, cardiovascular disease (CVD), and several 
types of cancer.  
The use of BMI alone as a marker of overweight and obesity is limited for, although it 
correlates well with total body fat content in adults, it fails to consider the distribution of 
that fat. In view of the relationship between central obesity and coronary heart disease 
(CHD), other methods of defining obesity have been used; for example, the waist 
circumference (WC) and waist-to-hip ratio. 
Two patterns of obesity have been distinguished for the purposes of risk factor 
assessment; namely, central (visceral) obesity and peripheral obesity. Central obesity 
produces a characteristic body shape which resembles an apple and thus is also referred to 
as “apple shaped” obesity: it is defined as deposition of fat around the trunk and in the 
visceral adipose tissue. It is more common in men and carries a higher risk of CHD, as 
well as various metabolic derangements including dyslipidemia and glucose 
intolerance.[5] In “pear shaped” obesity or peripheral obesity accumulation of fat is 
predominantly in the gluteo-femoral area. It is more common in women and is less 
strongly associated with cardiovascular risk. 
Men with a WC of > 102 cm and women with a WC > 88 cm have a higher risk of CHD, 
and a WHR of > 0.92 carries a nearly 3-fold increased risk (Figure 1).[6]   
Much interest has recently focused on the concept of “all obesity is not created equally”. 
Obese individuals without the metabolic abnormalities that commonly accompany excess 
adiposity, a condition known as metabolically healthy obesity (MHO), account for a 
substantial proportion of the obese adult population. Numerous possible mechanisms 
underlying MHO have been suggested, including adipose tissue distribution and 
inflammation.[7] 
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Figure 1: Classification of obesity developed by the National Heart, Lung and Blood 
Institute task force, along with the associated disease risk with increasing BMI, waist 
circumference and waist to hip ratio.[8] 
 
 
1.2. Prevalence Rates and Trends 
Over the last few decades, overweight and obesity increased worldwide and became a 
major public health challenge not only in high-income countries but also in middle- and 
low-income ones.  
The more recent US data are from the National Health and Nutrition Examination Survey, 
2011–2012. More than one-third (35%) of adults were obese and the prevalence of 
obesity was higher among middle-aged adults (40%). Data from NHANES II (between 
1976 and 1980) and NHANES III (between 1988 and 1994) demonstrate that the 
prevalence rates of obesity increased considerably, to about 21% in men and to about 
26% in women. By 2003–2004 the prevalence had increased to almost 32% in men and 
34% in women.[9] 
Among European countries, Italy had relatively favorable obesity prevalence and trends 
in adults The prevalence of overweight and obesity modestly increased between the early 
1980s (27% of adult population was overweight and 7% obese in 1983) and the late 
1990s and levelled off thereafter (31–34 % overweight and 8–9% obese between 1999 
and 2004). 
According to a recent epidemiological study published in Lancet, on 2013 in Italy the 
prevalence of overweight-obesity and obesity in > 20 year old male was respectively 
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58.3% and 18.6% and > 20 years old female was respectively of 41.4% and 17.7% 
(Figure 2).[10] 
 
 
Figure 2: Age-standardized prevalence of overweight and obesity and obesity alone, ages 
≥ 20 years, by sex, 1980−2013, modified from [10]. 
 
 
1.3. Pathogenesis 
Many different hypotheses have been proposed to explain the origin of the obesity 
epidemic. It’s broadly accepted that the two major putative contributors are specific food 
marketing and consumption habits, and decrease in physical activity. However, there are 
others contributors, such as infections and microbiota [11], maternal age, sleep debt, 
endocrine disruptors (such as industrial chemicals), reduction in ambient temperature 
variations, intrauterine and intergenerational effects, and drug-induced weight gain. 
Despite the importance of all these contributors, it is known that genetic factors have a 
key role in the risk of one becoming obese. 
Environmental factors are likely to be major contributors to the obesity epidemic, 
together with biological predisposition. It is certain that obesity develops when there is a 
positive imbalance between energy intake and energy expenditure, but the relative 
contribution of these factors is poorly understood. Evidence supports the contribution of 
both excess energy intake and decreased energy expenditure in determining obesity:  
1. Dietary data from four consecutive NHANES studies, consisting of 39,094 adults in the 
USA, have shown that the temporal trends in the increase of the quantity and energy 
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density of foods consumed by adults parallel the increasing prevalence of obesity in the 
US population.[12]  
2. Data from the Central Statistical Office show that car ownership and television 
viewing, proxy measures of physical inactivity, closely parallel the rising trends in 
obesity in England.[13]  
3. Using data from NHANES, Dietz et al. demonstrated that the prevalence of obesity 
increased by 2% for each additional hour of television viewed. [14] 
4. There is also evidence that the relative availability and price of different food products 
affect food consumption and that the built environment, such as quality of local parks, 
affects the level of physical activities in a community. 
These findings not only emphasize the impact of environmental factors on the obesity 
epidemic, but also indicate that policies affecting the availability of high caloric-density 
food, the cost of fruits and vegetables, and the built environment may contribute to the 
alarming prevalence rates of overweight and obesity. 
Common forms of obesity are caused by a combination of environmental factors with 
many gene variants of minor effect. However, at least ~ 7% of non-syndromic early-onset 
severe obesity are monogenic, thereby caused by gene variants of major effect (Figure 
3).[15]  
It is well-characterized that the obesity epidemic is not caused by single gene disorders, 
but actually has a complex genetic background. Obese children under three years of age 
without obese parents are at low risk for obesity in adulthood, but among older children, 
obesity is an increasingly important predictor of adult obesity, regardless of whether the 
parents are obese. Parental obesity more than doubles the risk of adult obesity among 
both obese and non-obese children under 10 years of age.[16] 
The effect of genes on the pathogenesis of obesity is more frequently stronger when 
combined with other genes and the environment. The ‘thrifty genotype hypothesis’ argues 
that the ancestors of present day humans in countries plagued by obesity underwent 
positive selection for genes that favored “thrift” or energy storage.[17] These so-called 
‘thrifty genes’ are defined as those that bestow superior energy efficiency such that the 
energy balance equation is shifted heavily toward energy intake as opposed to energy 
expenditure. It is postulated that survival of a population necessitated the selection for 
‘thrifty genes’ that enabled extra fat reserves to be laid down during times of energy 
surplus to be utilized during harder times.  
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 Figure 3: Rare non-syndromic forms of early-onset obesity, modified from [18]. 
 
 
1.4. Complications  
Numerous studies have demonstrate d increased mortality above a certain threshold of 
BMI. In the Framingham heart study, a prospective cohort study, male and female non-
smokers aged 40 year who were obese lived 5.8 and 7.1 years less than their non-obese 
counterparts.[19] Another study by Fontaine et al. which used data from the National 
Health and Nutrition Examination Survey (NHANES I and II) and the NHANES III 
Mortality Study found a marked reduction in life expectancy in obese young adults 
compared to non-obese adults.[20]  
Obesity increases risk for many disorders that are associated with high mortality and 
morbidity, including diabetes, hypertension, coronary heart disease, dyslipidemia, 
gallbladder disease, and certain malignancies (Table 2). Not only does excess weight 
increase the risk of these disorders, but the pattern of fat distribution is important in many 
of these conditions. Men are more likely to have abdominal or upper-body obesity, 
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whereas women are more likely to have a gluteo-femoral or lower-body pattern of fat 
distribution. However, as women gain weight, they become more likely to develop 
abdominal and upper-body fat. 
Insulin resistance/hyperinsulinemia 
Type 2 diabetes  
Hypertension  
Dyslipidemia  
Coronary heart disease 
Stroke  
Gallbladder disease 
Cancer (postmenopausal breast, ovarian endometrial, gastric and esophageal, colon, 
kidney, prostate) 
Osteoarthritis 
Chronic venous insufficiency 
Thromboembolism  
Asthma 
Obstructive sleep apnea 
Breathing difficulties 
Complication of pregnancy  
Menstrual irregularities 
Hirsutism 
Increased surgical risk 
Psychological distress 
 
Table 2. Disorders associated with obesity, modified from [21]. 
 
 
1.4.1. Arterial and venous vascular complications 
In 2015 Dagenais et al. studied the impact of increased BMI and waist circumference on 
the occurrence of cardiovascular death, myocardial infarction, stroke, heart failure, and 
total mortality among 8802 men and women with cardiovascular disease enrolled in the 
Heart Outcomes Prevention Evaluation (HOPE) study and observed during a median 
period of 4.5 years. In these individuals with CVD, elevated BMI was an independent 
predictor only for myocardial infarction when not adjusted for abdominal obesity indexes. 
Similarly, increased WC was independently related to cardiovascular death, myocardial 
infarction, and total mortality. Abdominal obesity and increased BMI to a lesser degree 
worsen the prognosis of patients with CVD.[22] The mechanisms by which increasing 
body weight contributes to higher risk of CVD, independent of other prognostic factors, 
are not fully understood. It is possible that obesity, particularly adipocytes, activates 
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coagulation, inflammation, and the sympathetic and renin-angiotensin aldosterone 
system.[23] Being overweight and obese are also associated with coronary endothelial 
dysfunction, hyperinsulinemia, and other metabolic disorders.[24] 
In previous studies, only obesity has consistently been demonstrated to be an independent 
risk factor for venous thromboembolic events. It’s known that a positive association 
between diabetes and deep vein thrombosis,[25] arterial hypertension and the risk of 
pulmonary embolism,[26] and dyslipidemia and venous thromboembolism (VTE).[27] 
Elevated levels of triglycerides and low high-density lipoprotein (HDL) seem to increase 
the risk of VTE, whereas increased HDL levels may protect against VTE.[28] Finally, it 
was described the association between the metabolic syndrome, a cluster of risk factors 
for atherosclerosis, and unprovoked deep vein thrombosis.[29] 
It is generally believed that the genesis of venous thromboembolism differs from 
atherosclerotic cardiovascular disease.[30] The concept that venous thromboembolism 
and atherosclerosis are two completely distinct entities has recently been challenged 
because patients with spontaneous VTE have been found to have a higher prevalence of 
atherosclerosis, defined by the presence of asymptomatic carotid atherosclerotic lesions, 
than patients with VTE secondary to known risk factors and control subjects.[31] 
In 2008 it was performed a systematic review of the literature to assess the relation 
between VTE, atherosclerosis and atherothrombosis: meta-analysis was conducted on 21 
case-control studies that evaluated the prevalence of cardiovascular risk factors, such as 
BMI, hypertension, diabetes, dyslipidemia and smoking, in subjects with prior venous 
thromboembolism. The results suggest that major risk factors for atherothrombotic 
disease also are significantly associated with VTE.  
In the past, only obesity has been consistently shown to be a minor risk factor for venous 
thrombosis, whereas conflicting results have been reported for hypertension, 
dyslipidemia, diabetes mellitus, and smoking. Ageno et al. confirmed the association 
between obesity and VTE but also demonstrated for the first time an association between 
VTE and diabetes mellitus, hypertension, low HDL cholesterol and high 
triglycerides.[32] 
From a laboratory perspective, an association between venous and arterial events is 
plausible because they share common characteristics such as activation of both platelets 
and coagulation.[33] 
The risk of arterial thrombosis in patients with major cardiovascular risk factors is most 
likely mediated by the presence of an inflammatory state and hypercoagulability. Both 
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increased inflammation and coagulation also may predispose these patients to develop 
venous thromboembolic events. Obesity, in particular central and abdominal obesity, is 
associated with increased thrombin formation and decreased fibrinolysis.[34] [35] 
Obesity also is associated with immobility and increased abdominal pressure, another risk 
factor for thrombosis. Diabetes mellitus often is associated with increased levels of 
procoagulant factors and the inhibition of endogenous fibrinolysis.[36] Dyslipidemia also 
is associated with hypercoagulability, endothelial dysfunction, and increased platelet 
aggregation.[37]  
It is therefore no surprise that these risk factors also predispose to VTE and can be 
considered part of the underlying disease process that is associated with cardiovascular 
disease and venous thromboembolism.
M1 
This association between VTE and 
atherothrombosis has great clinical relevance with respect to individual screening, risk 
factor modification, and the primary and secondary prevention of VTE. 
 
 
1.5. Coagulation tests  
There is a potential for significant paradigm shift in the assessment of hemostasis from 
the conventional plasma recalcification times, which correspond to artificially created 
compartments of hemostasis to tests that assess the entire process in a more physiological 
and holistic manner. Primary hemostasis consists of the interaction between platelets and 
vessel wall. Human platelets are critically involved in both normal hemostasis and 
pathological bleeding and thrombosis. These particular cells contribute greatly to vessel 
constriction and repair, host defense, and tumor growth/metastasis. In addition, platelets 
acting together with other cells - white, endothelial, or smooth muscle cells - play a part 
in inflammation, in related pathologies, and in the promotion of atherosclerosis. The rapid 
progression of these different capacities causes the activated platelets to form a 
hemostatic plug that occludes the site of injury to prevent blood loss.[38] An increased 
risk of bleeding could be present when platelet count is reduced and/or one of their 
functions is defective. Conversely, improper thrombus formation could be due to a growth 
in platelet count or reactivity. In particular, activated platelets adhere and aggregate within 
atherosclerotic lesions, forming occluding arterial thrombi that may result in 
thromboembolic disease such as stroke or myocardial infarction, two of the major causes 
of morbidity and mortality in the Western world.[38, 39] These different functions of 
platelets may be reliably detected with a wide spectrum of tests. The history of platelet 
18 
 
function testing begins with the development of the evaluation of the bleeding time by the 
Duke procedure.[40] For many years, it has been the unique screening test to identify 
both congenital or acquired platelet disorders. In the 1960s, the revolutionary platelet 
aggregation test in platelet rich plasma - ie, light transmission aggregometry - according 
to Born’s studies was the key method used to diagnose platelet function.[41] Since the 
late 1980s, other platelet function testing methods, such as platelet aggregometry in whole 
blood, the study of activated platelets ex vivo by flow cytometry, the measurement of 
specific compounds released by platelets, and the assessment of platelet nucleotides have 
become available (Figure 4). 
 
 
Figure 4: Different platelet function tests, modified from [42]. 
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1.5.1. Coagulation cascade and fibrinolytic system  
Hemostasis and its abnormalities have been traditionally assessed by plasma clotting 
times, such as the prothrombin, activated partial thromboplastin and thrombin times. 
The coagulation cascade has two initial pathways which lead to fibrin formation. These 
are the contact activation pathway (also known as the intrinsic pathway), and the tissue 
factor pathway (also known as the extrinsic pathway) which both lead to the same 
fundamental reactions that produce fibrin. The pathways are a series of reactions, in 
which a zymogen (inactive enzyme precursor) of a serine protease and 
its glycoprotein co-factor are activated to become active components that then catalyze 
the next reaction in the cascade, ultimately resulting in cross-linked fibrin. Anionic 
phospholipid, especially phosphatidylserine, was required for the assembly and optimal 
function of most of the coagulation complexes. 
A “Cascade model’’ was a great advance in our understanding of coagulation. This 
resulted from work that was aimed at elucidating the identity, function and interactions of 
the individual procoagulant proteins. [43] The coagulation “Cascade” models very well 
the screening coagulation laboratory tests, the prothrombin time (PT) and activated partial 
thromboplastin time (aPTT), which correspond to the extrinsic and intrinsic pathways 
(Figure 5). 
However these tests have several limitations. These include the fact that all of them are 
performed under conditions that are far from physiological, and they split the process of 
coagulation into artificial segments thus not assessing the potential impact of other 
components of the hemostatic system.[44] 
Furthermore, clotting times are insensitive to mild hemostatic disorders (e.g. carriers of 
hemophilia, mild liver disease) or to increased coagulability that leads to increased 
thrombosis risk (e.g. obesity, diabetes and metabolic diseases).  
High factor VII and factor VIII levels correlate with measures of obesity and an increased 
risk of CHD and stroke. High triglycerides and low high density lipoprotein (HDL) 
cholesterol, the most common lipid disturbances found in obesity, are also found with 
high factor VII and VIII levels. Fibrinogen promotes arterial and venous thrombosis 
through increased fibrin formation, platelet aggregation and plasma viscosity; and 
promotes atherosclerosis through vascular smooth muscle and endothelial cell 
proliferation.[45] [46] 
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Figure 5 : The cascade model of coagulation. The “intrinsic” and “extrinsic” pathways are 
reflected in the clinical laboratory tests aPTT and PT, respectively, adapted from[47] 
 
 
Obese patients exhibit increased tissue factor (TF)-mediated coagulation, with raised 
adipocyte and monocyte TF expression secondary to elevated levels of C-reactive protein 
(CRP), transforming growth factor-beta (TGFβ), tumor necrosis factor-alfa (TNF), 
angiotensin II and insulin.[48] 
Even if there were no differences in conventional plasma recalcification times, it is 
known that obesity and other metabolic diseases are correlated with prothrombotic state: 
conventional coagulation tests, such as PT and aPTT, do not reflect the suspected 
hypercoagulable state.  
If the main event in coagulation is considered to be fibrin formation by endogenously 
generated thrombin, the analogous step in fibrinolysis is fibrin degradation by plasmin. 
Fibrinolytic system is a parallel system which is activated along with activation of 
coagulation cascade and serves to limit the size of clot. The conversion of the inactive 
proenzyme plasminogen into the active enzyme plasmin is the central step in the 
fibrinolytic system. Plasmin degrades fibrin into soluble fibrin degradation products. Two 
physiologic plasminogen activators are capable of catalyzing the conversion of 
plasminogen: tissue-type and urokinase-type plasminogen activator (Figure 6).[49] 
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As long as blood coagulation and fibrinolysis remain in equilibrium, response to injury, 
such as blood vessel penetration, is appropriately self-limited. However, alterations in this 
balance may lead to a prothrombotic state or a bleeding tendency.  
PAI-1 is produced in several tissues including liver, spleen and adipocytes. Elevated PAI-
1 levels compromise the normal clearance of fibrin and consequently promote 
thrombosis.[48] 
PAI-1 levels are positively correlated with obesity (measured by BMI, WC and WHR), 
insulin resistance, and triglyceride levels.[50] High PAI-1 concentrations have been found 
in patients with recent myocardial infarction, chronic coronary heart disease and 
peripheral arterial disease.[51] 
A variety of methods have been proposed to assess fibrinolytic activity in blood or its 
components, but due to the complexity of the system, the design of a “gold standard” 
assay has remained an elusive goal. Assessment of fibrinolysis in whole blood is truly 
“global.” 
Finally, it is indispensable to remember that the hemostasis process is not only constituted 
by bioumoral coagulation factors but also different cell types play a key role. 
A cell-based model might describe the role of different kind of cells and reflects the 
pathways of hemostasis in vivo. Hemostasis occurs in three (overlapping) phases. The 
initiation of coagulation takes place on tissue factor (TF)-bearing cells, such as the 
fibroblast illustrated in Figure 7. TF is expressed on a variety of extravascular cells under 
normal conditions, and can also be expressed by blood monocytes and endothelial cells in 
inflammatory states. If the procoagulant stimulus is sufficiently strong, enough factors 
Xa, IXa and thrombin are formed to successfully initiate the coagulation process. 
Amplification of the coagulant response occurs as the “action” moves from the TF-
bearing cell to the platelet surface. The procoagulant stimulus is amplified as platelets 
adhere, are activated and accumulate activated cofactors on their surfaces. Finally, in the 
propagation phase, the active proteases combine with their cofactors on the platelet 
surface – the site best adapted to generate hemostatic amounts of thrombin. The activity 
of the procoagulant complexes produces the burst of thrombin generation that results in 
fibrin polymerization. Most conventional tests of blood coagulation explore specific 
stages of clotting cascade in plasma. This may represent a limitation for the study of 
coagulation processes in which the interactions between plasma factors and phospholipid 
surfaces act together with other blood components in clot formation. It is possible that 
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tests that assess global hemostasis may be better reflective the overall hemostatic 
potential of blood. 
 
Figure 6: Simplified fibrinolysis scheme, from [52]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: A cell-based model of coagulation, adapted from [53]. 
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1.5.2. Microparticles  
‘Microparticles’ (MPs) are fragments released from stimulated or apoptotic cells after 
plasma membrane remodeling. They consist of a cell-derived vesicle that is formed from 
the outward blebbing of the plasma membrane and subsequent shedding into extracellular 
space.[54] MPs range in size from 100 to 1000 nm in diameter, but are typically ~ 200 
nm in size. Hardly detectable in the peripheral blood of healthy individuals, procoagulant 
MPs circulating at elevated levels are often associated with different diseases.[55] The 
composition and the distribution of cell membrane phospholipids are highly specific: 
phosphatidylcholine and sphingomyelin are located on the external membrane layer, 
while phosphatidylserine (PS) and phosphatidyl-ethanolamine (PE) are found on the inner 
side of the cell membrane.[56] 
The preservation of this asymmetry is essential and is maintained through a complex 
transmembrane enzymatic balance. Five enzymes are involved in regulation of cell 
membrane phospholipid asymmetry and are implicated in microparticle generation: 
gelsolin (present only in platelets), aminophospholipid translocase, floppase, scramblase 
and calpain. These enzymes maintain a dynamic asymmetric steady state and allow 
membrane phospholipids to move to the outside of the cell membrane while at the same 
time, the aminophospholipids are redirected to the inner side of the cell membrane. When 
the concentration of calcium rises in the cytosol, for example during platelet activation, 
this steady state is changed and results in the expression of PS on the exterior membrane 
surface. Loss of phospholipid asymmetry arises during platelet activation, apoptosis and 
necrosis and results in exposure of PS on the outer cell surface and this leads in turn to a 
prothrombotic state. MPs contribute to hemostatic and inflammatory responses, vascular 
remodeling and angiogenesis, cell survival, and apoptosis, well-known processes 
involved in atherothrombosis (Figure 8).[57] 
MPs are enriched with bioactive proteins and nucleic acids, and there is growing evidence 
that they form a network of biological vectors able to transfer cellular components to 
remote areas of the body in order to mediate specific changes in their target cells, thus 
mediating cell activation, phenotypic modification, and reprogramming of cell function. 
Because microparticles readily circulate in the vasculature, they may serve as shuttle 
modules and signaling transducers not only in their local environment but also at 
remarkable distance from their site of origin.  
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a  
a) 
Calcium is stored in the endoplasmic 
reticulum. Scramblase is inactive, while 
Translocase is active. Translocase transports 
anionic phospholipid, such as 
phosphatidylserine and phosphatidyl-
ethanolamine, from the outside layer of the 
cell membrane to the inside, maintaining PS 
and PE inside. Each PS is transported with 
one molecule of ATP. Floppase is an ATP-
dependent protein that contributes to 
maintaining the physiological membrane 
asymmetry. 
b) 
Intracellular calcium increases released by 
endoplasmic reticulum. Calcium activates 
calpain and gelsolin. Calpain cleaves long 
actin filaments. Gelsolin cleaves the actin 
capping proteins. The raised cytoplasmic Ca
2+
 
also activates scramblase and inactivates 
translocase. Phospholipid asymmetry begins 
to be compromised. 
c) 
Spectrin and actin are cleaved. At this point 
protein anchorage to the cytoskeleton is 
disrupted allowing membrane budding. 
d) 
Generated microparticle expose 
phosphatidylserine on the external surface 
 
 
Figure 8: Schematic representation of the 
resting cytoskeleton, modified from [57]. 
b  
c  
d  
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Although microparticle formation represents a physiological phenomenon, MPs are 
hardly detectable in the peripheral blood of healthy individuals. They are released from 
cells under conditions of stress state. A multitude of pathologies are associated with a 
considerable increase in circulating microparticles, including inflammatory and 
autoimmune diseases, atherosclerosis and malignancies.[58] 
Believed to be formed by all cell types, MP formation has been observed in cells of the 
vasculature (endothelial cells, platelets, leucocytes and vascular smooth muscle cells), 
erythrocytes, cardiomyocytes and podocytes, as well as cancer and progenitor cell 
populations.[59] 
 
 
1.5.2.1. Platelet-derived microparticles  
Both the megakaryocytes and platelets can generate microparticles. Greater than 90% of 
circulating MPs are thought to be platelet derived, present in the plasma of normal 
healthy individuals at an estimated concentration of up to 50 mg/m. Platelet activation is a 
prerequisite in the afore mentioned mechanisms leading to microparticle production.[60] 
Platelet-derived microparticles (PMP) contain a unique subset of proteins derived from 
the parent cell: they express GpIb (CD42b), platelet endothelium adhesion molecule 
(PECAM-1; CD31) and P-selectin (CD62P) [61], CD63, CD41a and CD 61.  
PMP can transfer receptors from platelet membranes to different cell types and enhance 
engraftment of hematopoietic stem/progenitor cells, as well as confer adhesive properties 
with circulating tumor cells.[60] PMP promote monocyte and neutrophil adhesion to the 
endothelium and stimulate COX-2 expression in monocytes and endothelial cells. 
Furthermore, it was established that PMP could not only passively carry various proteins 
and receptors, but also chemoattract hematopoietic cells and stimulate their adhesion, 
survival, and proliferation.  
Higher concentrations of PMP have been documented in thrombophilic diseases in which 
platelets play a role, such as heparin-induced thrombocytopenia, thrombosis, idiopathic 
thrombocytopenic purpura,[61] but also in cardiovascular disease, for example in patients 
with peripheral arterial disease, unstable angina, myocardial infarction, cerebrovascular 
accident and diabetes.[62] 
Many studies have explored associations for platelet activation markers to gain insights 
on the pathogenesis of obesity and atherosclerotic disease.[63] Csongrádi et al. report on 
a large cross-sectional cohort study that explored relationships for platelet activation 
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markers in obese subjects, including those with and without common co-morbidities for 
atherosclerotic disease.[64] 
The extent of atherosclerotic disease, and the metabolic derangements associated with 
obesity and atherosclerotic disease, influence the generation of platelet microparticles. 
This possibility is supported by a study that showed weight loss-induced improvements in 
insulin resistance, among women with obesity, reduced markers of platelet activation. 
[65]  
 
 
1.5.2.2. PMP exposing P-selectin  
Soluble P selectin (sPsel) belongs to the selectin family of cell adhesion molecules. It is a 
membrane component of the platelet alpha granule and endothelial cell Wiebel - Palade 
body. It mediates binding to specific carbohydrate containing ligands, which is present on 
leukocytes and in smaller amounts on platelets.[66]  
Expression of P-selectin provide additional prothrombotic potential to microparticles. 
PMP exposing P-selectin (P-selectin+ MP) reflect platelet activation. Increased 
concentrations of circulating PMP P-selectin+ are found in peripheral arterial disease and 
myocardial infarction.[62] 
Platelets from obese individuals seem to be more reactive both at baseline and after 
aspirin, suggesting an innate platelet hyperaggregability.[67] Csongrádi et al. found 
“independent” associations between platelet-derived microparticle levels with BMI, and 
between soluble P-selectin and fibrinogen, and platelet P-selectin+ and both carotid 
intimal medial thickness and PAI-1: this provides evidence that platelet activation is 
influenced by the complex metabolic and inflammatory parameters that participate in the 
pathogenesis of atherosclerotic disease.[64]  
 
 
1.5.2.3. Endothelial-derived microparticles  
Endothelial cell microparticles (EMP) account for only 5% to 15% of the total MP. [68] 
They express different antigens, such CDs 31 and CD34, CD62E (E-selectin)[69], CD 
105 (endoglin) and CD146. EMP have different markers (qualitatively and quantitatively) 
depending on whether they are generated by cell activation processes or by apoptosis. It 
was found that in apoptosis, constitutive endothelial cell markers were increased on 
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microparticles (CD31 > CD105), whereas inducible endothelial microparticles markers 
were markedly increased during activation processes (CD62E > CD54 > CD106).[70] 
EMP, which play an important role in cell-to-cell communication and function, have 
confirmed procoagulant, proinflammatory, angiogenic and other functions, affecting 
pathological processes. 
When EMP expressing tissue factor, which is the initiator of the extrinsic coagulation 
pathway, they induce TF-dependent thrombin formation in vitro and in vivo.[71]  
EMP not only as a surrogate marker of endothelial dysfunction or injury but also as 
effectors able to amplify a pre-existing vascular dysfunction. Elevations in EMP are 
negatively correlated with flow-mediated vasodilation and positively correlated with 
pulse wave velocity and carotid intima-media thickness.[72] High levels of circulating 
MPs, from platelet, monocyte or endothelial lineages, were observed in patients with 
hypertension, EMP being features of both systolic and diastolic pressures. EMP in 
peripheral blood may be sensitive markers of the thrombo-occlusive vascular process 
developing in the coronary arteries of STEMI patients. EMP increase also in patients with 
congestive heart failure, in cerebral ischemia: EMP act as novel diagnostic and 
therapeutic biomarkers of circulatory hypoxia-related diseases. 
 
 
1.5.2.4. Leukocyte derived-microparticles 
Leukocyte-derived microparticles (LMP) may originate from neutrophils, monocytes and 
macrophages, and B- and T lymphocytes. They carry markers from their parental cells 
(Figure 9) and harbor membrane and cytoplasmic proteins as well as bioactive lipids 
implicated in a variety of mechanisms, maintaining or disrupting vascular homeostasis. 
When they carry tissue factor or coagulation inhibitors, they participate in hemostasis and 
pathological thrombosis. Both proinflammatory and anti-inflammatory processes can be 
affected by LMP, thus ensuring an appropriate inflammatory response. LMP also play a 
dual role in the endothelium by either improving the endothelial function or inducing an 
endothelial dysfunction. LMP are implicated in all stages of atherosclerosis. They 
circulate at a high level in the bloodstream of patients with high atherothrombotic risk, 
such as smokers [73], diabetics and subjects with obstructive sleep apnea [74], where 
their prolonged contact with the vessel wall may contribute to its overall deterioration. 
LMP modify the endothelial function and promote the recruitment of inflammatory cells 
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in the vascular wall, necessary processes for the progression of the atherosclerotic lesion. 
In addition, LMP favor the neovascularization within the vulnerable plaque and, in the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Cellular origin of LMP, modified from [75]. 
 
ruptured plaque, they take part in coagulation and platelet activation. Finally, LMP 
participate in angiogenesis.[75] 
They circulate at a high level in the bloodstream of patients with increased 
atherothrombotic risk or CVD: LMP might be useful in predicting cardiovascular events.  
 
 
1.5.2.5. Tissue factor-positive microparticles 
Tissue factor (TF) is a transmembrane protein that binds plasma factor VII/ VIIa. The 
TF:FVIIa complex activates both factor X and factor IX to initiate blood coagulation 
(Figure 5).[76] 
TF is normally expressed by extravascular cells or present in the blood in an encrypted 
form. It is constitutively expressed by certain cells within the vessel wall and cells 
surrounding blood vessels, such as vascular smooth muscle cells, pericytes, and 
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adventitial fibroblasts: this provides a primary hemostatic barrier around all blood vessels 
that rapidly activates blood coagulation after injury.  
TF is also expressed in a tissue-specific pattern with high levels in different organs, in 
particular, by astrocytes in the brain, epithelial cells in the lung, cardiomyocytes in the 
heart, and trophoblasts in the placenta to give additional hemostatic protection to these 
tissues. This distribution of TF is consistent with its essential role in hemostasis, because 
this limits inappropriate activation of the blood coagulation cascade.  
Pathologic conditions lead to induced TF expression by variety of vascular cells, and this 
expression plays an important role in thrombosis. In sepsis, TF is expressed by vascular 
cells, such as monocytes and endothelial cells. 
The presence of TF on MPs dramatically increases their procoagulant activity. TF has a 
high affinity for FVII/FVIIa, and therefore TF+MPs in blood will readily bind 
FVII/FVIIa.[77] 
Levels of TF+MPs are elevated in patients with a variety of diseases, including 
cardiovascular disease, diabetes, cancer, sickle cell disease, and endotoxemia. In cancer, 
TF+MPs are derived from tumors and may serve as a useful biomarker to identify 
patients at risk for venous thrombosis.[77] 
Many cell types can generate circulating TF+MPs. For instance, leukocytes, endothelial 
cells, platelets and vascular smooth muscle cells have all been shown to produce 
TF+MPs. The contribution of these different cell types to the pool of circulating TF+MPs 
may depend on the underlying disease.[76] 
 
 
1.5.2.6. Microparticles CD36+ 
CD36 is a transmembrane glycoprotein expressed on a variety of cells and tissues, 
including platelets, erythrocytes, monocytes, endothelial cells and leucocytes. It’s a 
multifunctional signalling molecule recognized by several known ligands, such as 
thrombospondin-1, long chain fatty acids, and lipoproteins, including HDL, LDL, and 
VLDL. Various studies described that CD36 is intimately involved in lipid metabolism 
and homoeostasis and implicated in pathological conditions associated with metabolic 
dysregulation, including obesity, insulin resistance, diabetes, diabetic nephropathy and 
atherosclerosis. Soluble CD36 (sCD36) was elevated in prediabetic conditions, including 
polycystic ovary syndrome, and was identified as a novel marker of liver injury in 
patients with altered glucose metabolism, so sCD36 could be used as a marker of the 
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metabolic syndrome and atherosclerosis. Alkhatatbeh et al. described that sCD36 was 
associated with the plasma MP fraction, suggesting that sCD36 in the plasma of normal 
subjects is a product of circulating MPs. Furthermore, CD36+MPs are readily detectable 
in diabetes mellitus, occurring at levels corresponding to approximately half that of PMPs 
and the origin was mainly from erythrocytes in mellitus diabetes as compared with 
endothelial cells in healthy controls.[78, 79] 
 
 
1.5.3. Thrombin generation 
Thrombin is a key enzyme in the coagulation process and leads to the conversion of 
fibrinogen to fibrin and clot formation. In the hemostatic mechanism there are no 
pathways that bypass thrombin. The measurement of the in vitro thrombin generation 
(TG) describes the potential of a sample to generate thrombin and may quantify the 
composite effects of multiple parameters of the coagulation system, so it reflects much, if 
not all, of the thrombotic-haemostatic function of the blood.[80] 
The Calibrated Automated Thrombogram (CAT) method is considered a test of global 
hemostatic capacity. This method describes the potential of a sample to generate thrombin 
and may quantify the composite effects of multiple parameters of the coagulation system, 
so it can reflect both thrombotic (high TG) and hemorrhagic (low TG) phenotype, 
therefore indicating both the increased risk of thrombosis and bleeding.[81]  
Specifically, it generates a thrombin generation curve that mimics the overall plasma 
coagulability potential when a thrombogenic stimulus appears (tissue factor, 
phospholipids and calcium chlorid) (Figure 10).[82] The thrombin activity can be 
measured in platelet-poor plasma by continuous cleavage of a low-affinity fluorogenic 
substrate for thrombin: the first derivative of the intensity of fluorescence is the TG curve. 
This curve is characterized by a lag (initiation) phase, followed by a thrombin burst 
(propagation), which is then eventually completely inhibited by plasma protease 
inhibitors (termination).[82]  
From this curve, various parameters can be inferred that describe thrombin activity, 
including: 
- lag time: the time until thrombin burst;  
- peak height: peak amount of thrombin generation (peak thrombin);  
- peak time: time thrombin takes to reach the peak;  
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- endogenous thrombin potential (ETP): the total amount of thrombin generated, 
represented by the area under the curve (AUC).[83] 
Shorter lag time and higher ETP and thrombin peak are indicator of a hypercoagulable 
state, on the other hand prolonged lag time and reduced ETP and peak are indicator of a 
hypocoagulable state. [44] 
 
 
 
Figure 10: Example of a thrombin generation curve obtained by means of the CAT 
method in normal individuals, adapted from [82]. 
 
Increase of thrombin generation is observed in deficiency of antithrombin as well as in 
congenital hyperprothrombinaemia. When thrombomodulin is added, thrombin 
generation becomes sensitive to all congenital and acquired (also oral contraceptives) 
disorders of the protein C system.[81] The thrombin generation test has great clinical 
potential, such as in monitoring patients taking anticoagulants and antiplatelet drugs, 
screening for genetic or acquired thrombotic disorders, and evaluating bleeding risk 
control in patients with hemophilia using bypass agents or replacement therapy. 
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1.5.4. Platelet function methods in conjunction with viscoelastic methodologies: 
thromboelastography and thromboelastometry  
Thrombelastography was first described by Hartert on 1948. The viscoelastic changes that 
occur during coagulation were recorded, providing a graphical representation of the fibrin 
polymerization process. The rate of fibrin polymerization as well as the overall clot 
strength is assessed.[84] 
The basic principle of thromboelastography involves incubation of whole blood or 
platelet rich plasma in a heated sample cup into which is suspended a pin. The pin and the 
cup or the cup alone oscillates, and as the blood clots, the motion of the cup is transmitted 
to the pin which is recorded via a computer. To perform thromboelastography, special 
equipment is needed, either a thromboelastograph (TEG®; Haemoscope Corporation, IL, 
USA) or rotation thromboelastometer (ROTEM®; Sysmex, Milton Keynes, UK). In the 
TEG®, a sensor (pin) is connected with a torsion wire, and clot formation generates a 
physical connection between the cup and sensor, which is recorded via a mechanical-
electrical transducer. In the ROTEM®, the pin (sensor) is fixed on the tip of a rotating 
shaft, whereas the sample cup is stationary and the position of the axis is detected by 
reflection of light on a small mirror on the axis.[52] 
The in vitro addition of specific reagents and activator to whole blood provokes the 
hemostatic activation followed by modifications in hematic viscoelastic forces: the entire 
process is instantly recorded during all clotting formation and also visualized in a typical 
curve. Different tests are available depending on the reagent used: tissue factor for 
extrinsic pathway (EXTEM test), different activators (glass, silica, kaolin, ellagic acid) 
for intrinsic pathway (INTEM test). The fibrin component of coagulation 
thromboelastometry (FIBTEM test) is used for the assessment of the specific role of 
fibrinogen in clot formation after the inhibition of platelets function.[85] 
The advantage that the TEG®/ROTEM® offers is its bedside capability to deliver within 
30 min a representation of the sum of platelet function, coagulation proteases and 
inhibitors, and the fibrinolytic system. The main uses of the TEG®/ROTEM® have been 
to monitor blood component therapy during surgery, such as liver transplantation, cardiac 
surgery and in trauma patients.[84] 
Among available ROTEM® parameters (Figure 11), the following were selected: 
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a) Clotting Time (CT, sec.), the time from the beginning of the coagulation analysis until 
an increase in amplitude of 2 mm, corresponding to the initiation phase of the clotting 
process;  
b) Clotting Formation Time (CFT, sec), the time in seconds between an increase in 
amplitude of thromboelastogram from 2 to 20mm;  
c) Maximum Velocity (MaxV, mm/min), the peak of the first derivative of the 
thromboelastographic clotting curve; the CFT and MaxV reflect measures of the 
propagation phase of whole blood clot formation;  
c) Maximum Clot Firmness (MCF, mm), the maximum amplitude in millimetres reached 
in the thromboelastogram which correlates with platelet count and function as well as 
with the concentration of fibrinogen; the MCF quantifies the maximum clot firmness of 
the established whole blood coagulum; 
d) Area under curve (AUC, mm*100), defined as the area under the velocity curve, that is 
the area under first derivative curve ending at a time point that corresponds to MCF, was 
also evaluated. 
‘Hypercoagulable profile was defined as CT or CFT shorter and/or MCF, MaxV or AUC 
higher than in the healthy controls.[84]  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Diagrammatic representation of a TEG®/ROTEM® trace indicating the 
commonly reported variables, derived from [84]. 
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Figure 12. Examples of abnormal ROTEM® traces, derived from [84]. 
 
 
1.5.5. Test based on a platelet aggregation: impedance whole blood aggregometry  
Impedance whole blood aggregometry allows one to assess platelet function by using the 
anticoagulated whole blood (WB) as milieu without any sample processing. 
The most commonly used method is light transmission aggregometry (‘Born’ 
aggregometry) employing citrated or heparinized platelet-rich plasma (PRP).[86] The test 
measures the change in light transmission in real time when agonists are added to PRP or 
washed platelets. A typical panel of agonists includes adenosin diphosphate (ADP), 
collagen, arachidonic acid, adrenaline, PAR-1 peptide, U46619 and ristocetin. The nature 
of the response is dependent on the agonist used, its concentration and the role of the 
feedback agonists ADP and thromboxane A2. Disadvantages of this technique include the 
need of centrifugation to separate other blood cells from platelets, which are also known 
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to influence platelet function. Besides, PRP does not contain all blood platelets: this 
usually leads to the loss of giant platelets which may be both hypo- and hyperactive.  
For these reasons, novel methods have been introduced to measure platelet aggregation in 
whole blood. One of these methods is impedance aggregometry, introduced by Cardinal 
and Flower.[87] As compared with PRP, impedance aggregometry in whole blood was 
more sensitive to the aggregating effect of thrombin, ristocetin and arachidonic acid, or to 
the inhibitory effect of prostacyclin or aspirin.  
It evaluates platelet responses in disposable ready-to-use test cuvettes, each containing 
two pairs of electrodes. The platelets, after activation by different agonists, adhere to the 
two copper wires of each of the two measuring units. During analysis, the instrument 
continuously measures the changes of the electrical resistance (called “impedance”) 
between the electrodes that is proportional to the amount of platelets adhering to each 
couple of electrodes. The impedance change determined by each sensor is recorded 
independently. Impedance aggregometry, as realized in commercial instruments (e.g. 
Chrono-log®) has some problems. The re-usable electrodes have to be cleaned between 
analyses, which is impractical and a possible source of error.  
For these reasons, a novel instrument to measure platelet aggregation in diluted whole 
blood has been developed. Due to the use of four electrodes per test cell, the technique is 
called “multiple electrode aggregometry” (MEA). The instrument is named 
“Multiplate®”, for “multiple platelet function analyzer”, indicating the multiplicity of 
channels and sensors per channel of the device.  
The mean values of the determinations are expressed in arbitrary “aggregation units” 
(AU). Increased electrical resistance is continuously monitored and reported as the area 
under the curve (AUC), that is used to express the aggregation response over the 
measured time (AU*min).[88] Monitoring antiplatelet therapies (e.g. aspirin) by using 
impedance has permitted the prediction of major adverse cardiovascular events in 
cardiovascular patients at high risk.[89] In addition, MEA has not only been able to 
identify cardiovascular patients not responding to antiplatelet agents and at risk of major 
adverse cardiovascular events, but has been considered a skill assay to distinguish those 
patients with a high inhibition of platelet function and at risk of bleeding. 
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1.6. Adipose tissue and low grade chronic inflammation  
Physiologically, adipose tissue (AT) stores energy to support metabolic requirements in 
the times of need. From an evolutionary point of view, this is beneficial, but with 
increased nutrient intake and reduced energy expenditure in our modern world, adipose 
tissue expands and his function becomes altered.  
AT secretes a variety of bioactive peptides, known as adipokines, which act at both the 
local (autocrine/paracrine) and systemic (endocrine). Moreover, it expresses numerous 
receptors that allow it to respond to afferent signals from traditional hormone systems. AT 
contains the metabolic mechanisms to permit communication with different organs. 
Through this interactive network, it is integrally involved in coordinating a variety of 
biological processes including energy metabolism, neuroendocrine function and immune 
function. Adipose tissue contains connective tissue matrix, nerve tissue, stromovascular 
cells, and immune cells. Although adipocytes secrete different kind of endocrine 
hormones, many secreted proteins are derived from the non-adipocyte fraction.[90] These 
components function as an integrated unit, making adipose tissue a true endocrine organ. 
In obesity dysfunctional adipose tissue is considered one of the primary origins of the 
metabolic disturbances that are present in the metabolic syndrome, such as insulin 
resistance and hyperglycemia, dyslipidemia, hypertension and prothrombotic and 
proinflammatory state.[91] AT dysfunction is thus characterized by decreased release of 
homeostatic protective factors such as adiponectin, nitric oxide, or protective 
prostaglandins and increased activation of stress related pathways leading to pathological 
adipokine release (leptin, resistin, visfatin) and development of low-grade inflammation. 
 
 
1.6.1. Leptin 
Leptin is a 16-kDa polypeptide containing 167 amino acids with structural homology to 
cytokines and it is the product of the OB gene. Circulating levels of leptin parallel fat cell 
stores, increasing with over feeding and decreasing with starvation. It acts mainly at the 
level of the central nervous system to regulate food intake and energy expenditure: leptin 
levels rapidly decrease with caloric restriction and weight loss. This decline is associated 
with adaptive physiological responses to starvation including increased appetite and 
decreased energy expenditure. These same responses are observed in leptin-deficient 
mice and humans, despite massive obesity. Furthermore, these responses are readily 
normalized by low dose leptin replacement. In contrast, common forms of obesity are 
37 
 
characterized by elevated circulating leptin. Neither endogenously high leptin levels nor 
treatment with exogenous leptin is effective in ameliorating this obesity, consistent with a 
state of leptin resistance. [92] 
The absence of leptin or a mutation in leptin receptor genes induces a massive 
hyperphagia and obesity in animal models, and humans [93], however, the prevalence of 
these mutations in obese humans is rare. 
Adipocytes secrete leptin in direct proportion to adipose tissue mass as well as nutritional 
status. mRNA expression is higher in subcutaneous adipose tissue than in visceral adipose 
tissue in human Leptin’s secretion is regulated by a variety of factors. For example, it is 
increased by insulin, glucocorticoids and tumor necrosis factor  and decreased by β3-
adrenergic activity, androgens, and GH.  
Although leptin acts mainly to regulate food intake, numerous other important endocrine 
effects of leptin include regulation of hematopoiesis, immune function, angiogenesis and 
bone development. The increased risk of cardiovascular disease with obesity makes 
adipokines, including leptin, an attractive instigator of atherosclerosis. In a large 
prospective study, leptin was independently associated with an increased risk of coronary 
artery disease. There is a relationship between leptin and the low grade inﬂammatory state 
in obesity, suggesting that it could exert peripheral biological effects as a function of its 
cytokine-like structure.[94] It was described that platelets express the leptin receptor and 
leptin potentiates the aggregation of platelets from ob/ob (knocked out for ob gene) mice 
in response to known agonists.[95] Furthermore, leptin can induce dose-dependent 
platelet stimulation in healthy subjects, but this effect was reduce in overweight and obese 
patients.[96] 
 
 
1.6.2. Tumor necrosis factor 
Tumor necrosis factor α (TNFα) is a 26-kDa transmembrane protein that is cleaved into a 
17-kDa biologically active protein that exerts its effects via type I and type II TNFα 
receptors. TNFα is a pro-inﬂammatory cytokine produced by a variety of cell-types: 
within adipose tissue, TNF is expressed by adipocytes and stromal vascular fraction.[90]  
Although initially suspected of playing a role in cachexia, TNFα has now been implicated 
in the pathogenesis of obesity and insulin resistance. Chronic exposure to TNFα induces 
insulin resistance both in vitro and in vivo.[97]  
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This effect is mediated by activation of serine kinases that increase serine 
phosphorylation of insulin receptor substrate-1 and -2, making them poor substrates for 
insulin receptor kinases and increasing their degradation. Moreover, TNFα influences 
gene expression in metabolically important tissues such as adipose tissue and liver. It 
represses genes involved in uptake and storage of nonesterified fatty acids (NEFAs) and 
glucose, suppresses genes for transcription factors involved in adipogenesis and 
lipogenesis, and changes expression of several adipocyte secreted factors including 
adiponectin and interleukin-6.[98] 
 
 
1.6.3. Interleukin-6 
Interleukin-6 (IL-6) circulates in multiple glycosylated forms ranging from 22 to 27 kDa 
in size. 
IL-6 is produced by many cell types (ﬁbroblasts, endothelial cells, monocytes), and many 
tissues including adipose tissue. Secretion is higher in visceral adipose tissue than in 
subcutaneous adipose tissue and macrophages contribute approximately 50% of white 
adipose tissue-derived IL-6.  
It is now well known that IL-6 production by adipose tissue is enhanced in obesity. 
Adipose tissue IL-6 expression and circulating IL-6 concentrations are positively 
correlated with obesity, impaired glucose tolerance, and insulin resistance. Both 
expression and circulating levels decrease with weight loss.  
IL-6 is a multifunctional cytokine acting on many cells and tissues. One of the main 
effects of IL-6 is the induction of hepatic C-reactive protein production, which is an 
independent major risk marker of cardiovascular complications. IL-6 also decreases 
insulin signaling in peripheral tissues by reducing expression of insulin receptor signaling 
components and inducing suppressor of cytokine signaling 3, a negative regulator of both 
leptin and insulin signaling.[90] 
 
 
1.6.4. High-sensitivity C-reactive protein (hs-CRP) 
C-reactive protein (CRP) has emerged as the main acute phase reactant inflammatory 
marker in clinical practice. It’s produced by the liver and the serum levels of this protein 
increase over 100-fold in response to tissue injury, infection, inflammation and neoplastic 
proliferation. The measurement of serum CRP concentrations is inexpensive and is done 
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routinely to assess patients. Many studies have demonstrated the positive association 
between CRP with various measures of obesity, obesity related disease, and 
cardiovascular risk. In addition, the serum high-sensitivity C reactive protein (hs-CRP) 
level is known to be a predictive marker of the degree of atherosclerosis and future 
cardiovascular events. It’s known that it has been associated with obesity, insulin 
resistance and cardiovascular dysfunction and several studies have also observed that 
elevated CRP predicts the prognosis of patients with CVD at the acute stage.[99] 
 
 
1.7. Treatment of obesity  
Patients with obesity needs a stepped intensification of care approach to weight 
management. If the patient is not able to achieve the weight and health goal by life-style 
alone and meets the indications for drug therapy, then addition of adjunctive 
pharmacotherapy should be considered. As a last step, bariatric surgery can be considered 
for subjects with complications and who meet its indications. A multidisciplinary 
approach that addresses psychological, social, environmental and biological factors of 
obesity is critical to ensure comprehensive care, as well as best practices and outcomes. 
 
 
1.7.1. Lifestyle  
The target of obesity care is assisting patients in making healthier dietary and physical 
activity choices that will lead to a net negative energy balance. Lifestyle education, 
provided in individual or group sessions by a trained health worker, is aimed to improve 
physical activity level, eating behaviors, healthy diet, stress management, and sleep. The 
initial goal is to achieve a 5% to 10% weight loss over the initial 6 months of 
treatment.[8] Caloric reduction is the most important component in achieving weight loss 
whereas increased and sustained physical exercise is particularly important in maintaining 
the lost weight. The dietary prescription will vary according to the patient's metabolic 
profile and risk factors. Weight loss is primarily dependent on reducing total caloric 
intake, not the proportions of carbohydrate, fat, and protein in the diet. Moreover, several 
studies support the evidence that promoting eating habits consistent with Mediterranean 
diet nutrients pattern may be a useful and safe strategy for the treatment of obesity.[100] 
A consultation with a dietitian for medical nutrition therapy is particularly useful along 
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with the importance of emphasizing collaborative care and self-management of chronic 
disease. 
In addition to reducing caloric intake, patients are also encouraged to burn more calories. 
There is a distinction between physical activity and exercise and weight loss counselling 
should encourage both aspects as part of treatment. Whereas physical activity consists of 
any bodily movement that increases energy expenditure, for example activities of daily 
living like walking, climbing stairs and gardening, while exercise is defined as planned, 
structured and repetitive bodily movement done to improve or maintain one or more 
components of physical fitness. Studies have demonstrated that lifestyle activities are as 
effective as structured exercise programs in improving cardiorespiratory fitness and 
weight loss.
M2
 
 
 
1.7.2. Pharmacotherapy 
Non-pharmacological treatment of obesity can be effective, but the long-term success rate 
is low and regaining lost weight is a major problem. Randomized studies have shown that 
a greater initial weight loss achieved with changes in lifestyle associated with other 
strategies (for example, anorectic drugs) improves long-term weight maintenance, 
provided that it is followed by a 1-2 years of integrated weight maintenance program 
consisting of lifestyle interventions involving dietary change, nutritional education, 
behavior therapy and increased physical activity. A greater initial weight loss as the first 
step with a pharmacological intervention may result in improved sustained weight 
maintenance.  
Pharmacotherapy is approved for patients with a BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 when 
complicated by an obesity-comorbidity. It is clearly stated that medications should be 
approved by the regulatory agencies, and clinicians should know what the benefits and 
health risks of the prescribed medication are. Medications work to reinforce lifestyle 
change and should be prescribed only as an adjunct to a good quality lifestyle 
intervention.[101]  
Factors leading to the development of obesity have been extensively studied in recent 
years. The central regulation of appetite, especially with regard to the hedonic appetite, is 
a field highly exciting. Recently, new medications have been approved for the treatment 
of obesity in the United States: orlistat, liraglutide, phentermine/topiramate, 
naltrexone/bupropion and lorcaserin. 
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1.7.3. Bariatric surgery 
In adults, bariatric surgery is extremely effective compared to conservative treatment, 
resulting in adequate long-term weight loss and reduction of mortality. Surgical 
approaches to treat obesity were first reported in Sweden in 1952. Actually, indications 
for bariatric surgery are reserved for patients with BMI ≥ 40 kg/m2 or with BMI ≥ 35 
kg/m
2
 with co-morbidities in which surgically induced weight loss is expected to improve 
the disorder (such as metabolic disorders, cardiorespiratory disease, severe joint disease, 
obesity-related severe psychological problems).  
The former classification of operations according to their influence on food ingestion, 
defined as:  
- limiting stomach capacity (restrictive surgery): adjustable gastric banding and sleeve 
gastrectomy (SLG),  
- limiting absorption of nutrients (malabsorptive surgery): biliopancreatic diversion 
(BPD) and BPD/duodenal switch (BPD-DS);  
- combined procedures: Roux-en-Y gastric bypass (RYGB). 
Anyway, this classification not appropriately reflects the current level of knowledge about 
early and 
weight-independent metabolic effects of these operations. Nowadays, most of the 
standard surgical interventions are being mostly referred to as metabolic operations. 
 
 
1.7.3.1. Sleeve Gastrectomy  
Sleeve gastrectomy (SLG) (Figure 13) was first performed by Hess in 1988 as part of his 
biliopancreatic diversion with the duodenal switch (BPD-DS) procedure, adapted from 
Scopinaro’s biliopancreatic diversion (BPD) and DeMeester’s duodenal switch (DS) 
procedures.[102] SLG consists of removing 80% of the stomach along the greater 
curvature, creating a tube-like stomach remnant, with the rest of the intestine intact. 
Weight loss induced by SLG was initially ascribed exclusively to a restrictive action: 
gastric volume reduction leads to reduced food intake. However, it has been demonstrated 
that both the resection of the gastric fundus and the rapid emptying of the stomach 
promote significant neuro-hormonal changes: by removing the gastric fundus, SLG 
induces a significant decrease in the circulating levels of ghrelin, the hormone of appetite, 
and an increased satiety through a food-mediated release of glucagon-like peptide-1 
(GLP-1) and peptide YY (PYY) from the L cells of the small intestine. These changes 
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persist 1 year after surgery, showing that SLG can be considered a “food-limiting” 
operation rather than a restrictive procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Sleeve gastrectomy. 
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2 AIM 
The objectives of this study were to evaluate global hypercoagulability in overweight and 
obese patients with and without metabolic syndrome by measuring: a) the levels of MP of 
different cellular origin and TF-bearing MP as well as MP functional activity and the 
levels of FVIIa-AT complexes, as an indirect measure of TF activation; b) thrombin 
generation as a general marker of hypercoagulability by measuring thrombin generation 
by the calibrated automated thrombogram (CAT) method; c) altered platelet aggregability 
by whole blood rotation thromboelastometry (ROTEM) and by impedence 
aggregometry (Multiplate). 
Furthermore, in order to evaluate the effect of weight loss, the aim of this study was to 
prospectively evaluate the levels of MP of different origin as well as their functional 
activity in a group of 20 II degree obese patients. 
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3 PATIENTS AND METHODS 
3.1  Study participants 
Eighty patients of both sexes referred to the Centre for the Study and the Integrated 
Treatment of Obesity of the Padua University Hospital between January 2011 and 
December 2012 for a cardiovascular evaluation were enrolled in this study. 
Inclusion criteria were: 
a) BMI ≥ 25 kg/m2; 
b) age between 18–70 years; 
c) their informed consent. 
These subsequent exclusion criteria were considered: 
 acute or previous [namely, acute (< 3 months) or previous (> 3 months)] 
cardiovascular disease or ischemic complications; 
 acute or previous venous thromboembolism; 
 infections or inflammatory disease; 
 severe blood hypertension (≥ 160/100 mmHg); 
 diabetes mellitus (ongoing anti-diabetic medications or glycohemoglobin test ≥ 
6.5%); 
 cancer; 
 recent surgery (≥ 3 months if major surgery, ≥ 1 month if minor surgery) or previous 
bariatric surgery; 
 anticoagulation, antiplatelet or steroid therapy; 
 pregnancy and/or puerperium, estroprogestinic therapy at the time of sampling or in 
the preceding three months. 
Eighty consecutive patients were included in the study. Twenty (25%) patients were 
overweight (BMI = 25-29.9 Kg/m2); 20 (25%) were I degree obese (BMI = 30-34.9 
Kg/m2); 20 (25%) were II degree obese (BMI = 35-39.9 Kg/m2) and 20 (25%) were III 
degree obese (BMI ≥ 40 Kg/m2). 
A control group of 40 consecutive normal weight subjects (BMI < 25 kg/m2) matched for 
age (± 3 years), sex and ethnic origin referred to our Centre for diet advice or for the 
evaluation of their cardiovascular risk was recruited. They were free from listed exclusion 
criteria. 
In order to evaluate the levels of MP of different origins as well as their functional 
activity in obese patients, before and after weight loss, other 20 patients referred to our 
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Centre in the same period were enrolled in this study. Inclusion criteria were a BMI > 40 
kg/m2, age > 18 years and an informed consent. All subjects enrolled were free from 
exclusion criteria. Patients were examined at enrollment (T0) and after 3 and 12 months 
(T3 and T12) post-sleeve gastrectomy.. 
A detailed history was collected from patients and controls in order to assess dietary 
habits, physical activity and medication in the seven days prior to blood sampling. Active 
exercise was defined as completing at least 90 minutes (min) of primarily aerobic lower 
body exercise over 3 days per week. Physical activity was self-reported. Blood pressure 
(BP) was measured in the same way in all subjects. 
The study protocol was approved by the Institutional Ethical Committee of the Padua 
University Hospital. 
 
 
3.2 Anthropometric parameters 
Anthropometric parameters such as BMI, waist circumference, systolic and diastolic 
blood pressure, after overnight fasting, were measured in all cases and control. Weight 
and height were measured by standard scales. BMI was calculated by dividing body 
weight (kg) by height squared (m) and classified according to the cutoff points proposed 
by the World Health Organization (WHO).[3] Waist circumference was measured 
between the last rib and the iliac crest using a flexible and inelastic tape measure. BP was 
measured in both arms after sitting for 5 min; at least two measurements were taken, with 
a 1-min interval between them, and the average of the measurements recorded. 
 
 
3.3 Metabolic analysis 
Biochemical tests including total cholesterol, low-density lipoproteins, high-density 
lipoproteins, triglycerides, fasting blood glucose (reference values [r.v.] ≤ 100 mg/dl), and 
insulin were measured after overnight fasting in all cases. 
Total cholesterol (r.v. ≤ 200 mg/dl), LDL (r.v. ≤ 100 mg/dl) and triglycerides (r.v. ≤ 150 
mg/dl) evaluation was carried out on an automated analyzer (DAX, Bayer, Pittsburgh, PA, 
USA) using commercial reagents (Randox Laboratories, Co. Antrim, UK). HDL (r. v. ≥ 
40 mg/dl) was measured using commercially available reagents (Wako Corp., Osaka, 
Japan). Insulin resistance was defined by a homeostasis model assessment index [HOMA-
IR: plasma glucose (mmol/l) x insulin (mU/l)/22.5] > 2.4.[103] 
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Metabolic syndrome was defined following the National Cholesterol Education 
Program/Adult Treatment Panel III (NCEP/ATP III) criteria (three of the following: waist 
circumference ≥ 102 cm for European men and ≥ 88 cm for European women; raised 
triglyceride level ≥ 150 mg/dl; reduced HDL cholesterol: < 40 mg/ dl in males and < 50 
mg/dl in females; raised blood pressure: systolic ≥ 130 or diastolic ≥ 85 mmHg; raised 
fasting plasma glucose: ≥ 100 mg/dl or previously diagnosed type 2 diabetes).[104] 
Plasma levels of interleukin-6 (IL-6) (r.v. < 5.9 ng/l), TNF (r.v. < 8.1 ng/l) and leptin (r.v. 
2 - 15 μg/l) were measured by ELISA (R&D Systems, Minneapolis, MN, USA). High-
sensitive C reactive 
protein (hs-CRP) (r.v. < 3 g/l) was measured by a turbidimetric assay on the Integra 800 
analyzer (Roche, Basel, Switzerland). White blood cells and platelet count (r.v. 4.5 - 
10.0*109/l and 150 - 450 × 109/l, respectively) were measured on the Sysmex Counter 
XE-2100 (Dasit Spa, Milan, Italy). 
 
 
3.4 Coagulation parameters 
Nine ml of venous blood was drawn directly in the laboratory from the antecubital vein 
with a light tourniquet, using a butterfly device with 21-gauge needle without venostasis. 
The first few ml were discarded to avoid the contact phase activation. Blood was 
collected directly into syringes pre-filled with 1 ml of sodium citrate 109 mol/l. Vacuum 
collection tubes were not used because of possible artificial cellular disruption and 
formation of MP by this collection method. Platelet-poor plasma (PPP) was prepared 
within 1 hour of blood collection by double centrifugation (2 × 15 min at 2,500 g) at 
room temperature. Prothrombin time (PT) (r.v. 70 - 100 %), partial thromboplastin time 
(PTT) (r.v. 24.4 - 36.5 seconds), fibrinogen activity (r.v. 150 - 450 mg/dl), factor VIII 
activity (r. v. 60 - 160 %), and antithrombin activity (AT) (r.v. 80 - 120 %) were 
measured, using fresh unfrozen plasma, in all samples as previously described. [105] 
Aliquots (1.5 ml) were immediately frozen and then stored at - 80 °C until use. Samples 
were thawed by incubation for 5 min in a water bath at 37ºC immediately before assay. 
Assays were performed at least one month after storage at - 80 °C. Samples were 
analyzed only after a single freeze-thaw cycle, and repeated freezethaw cycles were 
avoided. Patient and control samples were all Processed in the same way by the same 
experienced operators. The investigators who performed the laboratory tests were 
unaware of the obesity status of the patients. The FVIIa-AT complex was measured by 
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ELISA (Asserachrom FVIIa-AT, Stago, Asnieres, France). Factor VIIa activity (FVIIa:act 
r. v. 60–108 mU/ml) was determined in plasma by a clotting assay (STA-Clot® VIIa-rTF, 
Diagnostica Stago, Asnieres, France) performed on an ACL 3000 Research (IL, Milan, 
Italy) according to the protocol supplied by the manufacturer. 
 
 
3.5 MP assessment and characterization 
MP were identified by size and annexin V- fluorescein isothiocyanate (FITC) (Bender 
MedSystems GmbH, Vienna, Austria) labelling. To measure the different populations of 
MP, the MP were colabelled with antibodies against cell-type specific antigens and 
annexin V. Thirty μl of freshly thawed PPP were incubated for 15 min at room 
temperature in the dark with 3 μl of monoclonal antibodies against cell-type specific 
antigens and 3 μl of annexin V-FITC (AMP). Platelet-derived MP were identified using 
CD61-PE (phycoerythrin) (PMP) and CD62P-PE (P-selectin+) -both from Beckman 
Coulter (Miami, FL, USA); Endothelial-derived MP (EMP) using CD62E-PC5 
(phycoerythrin-cyanin 5.1) (Beckman Coulter); Leukocyte-derived MP (LMP) using 
CD45-PC5 (BioLegend Europe, Uithoorn, The Netherlands) and Tissue factor-bearing 
(TF+ MP) with CD142-PE, (clone HTF-1, BD, Biosciences, Milan, Italy). An antibody 
against CD36 (clone NL07) conjugated to eFluor 660 was used to determine CD36+MP. 
The isotype controls used were IgG1-PC5, clone MOPC-21 (BioLegend Europe), IgG1-
PE, clone MOPC-21 (BD Biosciences, Milan, Italy); mouse IgG1-FITC, clone MOPC-21 
(BioLegend Europe).The final concentration of monoclonal antibodies ranged from 1 to 4 
μg/ml. The samples were diluted in 500 μl of annexin-V kit binding buffer (Bender 
MedSystems GmbH) before analysis. Thirty μl of counting beads with an established 
concentration (Flow Count TM Fluorospheres, Beckman Coulter) were added to each 
sample in order to calculate MP as absolute numbers per μl of PPP. The MP gate was 
established using a blend of mono-dispersed fluorescent beads of three diameters (0.5, 0.9 
and 3μm) (Megamix, BioCytex, Diagnostica Stago). All assays performed on a Cytomics 
FC500 flow cytometer (Beckman Coulter) as previous described.[106] 
 
 
3.6 MP procoagulant activity 
Procoagulant activity of the MP was measured using the STA® Procoag PPL assay 
(Diagnostica Stago). The assay measures the clotting time in a system dependent on the 
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procoagulant phospholipid content of the sample. The assay is performed using a 
phospholipid depleted substrate plasma to eliminate the influence of any coagulation 
factors upstream. Factor Xa, in the presence of calcium, triggers the coagulation cascade 
and a shortening clotting time of the sample indicates an increased concentration of 
procoagulant phospholipids - a shorter clotting time indicating increased PPL activity. 
This activity linearly correlates with the functional activity of MP present in the 
sample.[107] 
 
 
3.7 Thrombin generation assay (CAT) 
Thrombin generation (TG) was determined in PPP using the CAT method (Diagnostica 
Stago). [108] Eighty μl of PPP were pipetted into the well of a microtiter plate together 
with 20 μl of PPP Reagent (Thrombinoscope BV), a mixture of tissue factor (5pM final 
concentration per assay) and synthetic phospholipids (4 μM final concentration in the 
assay). The reaction was started with 20 μl of a mixture composed of the fluorogenic 
thrombin substrate (Z-Gly-Gly-Arg-AMC, Thrombinoscope BV) and CaCl2 (final 
concentrations 417 μM fluorogenic substrate and 16 mM CaCl2). Fluorescence was read 
in a Fluoroscan Ascent® reader (Thermo Labsystems, Helsinki, Finland) and TG curves 
were calculated using the Thrombinoscope Software (Thrombinoscope BV). A Thrombin 
Calibrator (Thrombinoscope BV) was used in order to compensate for any quench by the 
patient PPP. Using the Thrombin calibrator as a reference, the concentration of thrombin 
was continuously calculated during the time course of measurement. TG curves were 
plotted and the lag time (min), peak thrombin (nMol) and endogenous thrombin potential 
(ETP, area under the curve, nM*min) were recorded. Shorter lag time and higher ETP and 
thrombin peak are indicator of a hypercoagulable state, on the other hand prolonged lag 
time and reduced ETP and peak are indicator of a hypocoagulable state.[44] 
 
 
3.8 Thromboelastometry (ROTEM®) 
Viscoelastic clotting measures were performed by ROTEM® (Tem International 
GmbH,Munich, Germany) tests according to the manufacturer’s protocol. In particular, 
whole blood (WB) was incubated at 37°C in a heated cup. Within the cup is suspended a 
pin connected to an optical detector system. The cup and pin are oscillated relative to 
each other through an angle of 4°45”. As fibrin forms between the cup and pin, the 
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transmitted impedance of the rotation of the pin is detected at the pin and a trace 
generated. All investigations were performed within two hours after blood collection and, 
once initiated, the blood coagulation was allowed to run until 60 min. Extrinsic 
coagulation cascade was studied with EXTEM test (ex-TEM®; Tem International GmbH) 
and intrinsic coagulation cascade was studied with INTEM test (in-TEM®; Tem 
International GmbH). The influence of fibrinogen on clot firmness was estimated with the 
platelet-inactivating FIBTEM test (fib-TEM®; Tem International GmbH), as previous 
described. 
The following ROTEM® parameters were analyzed: i) Clotting time (CT, sec), ii) Clot 
Formation Time (CFT, sec), iii) Maximum Velocity (MaxV, mm/min), iii) Maximum Clot 
Firmness (MCF, mm), iv) Area Under the Curve (AUC, mm*100). “Hypercoagulable 
profile” was defined as CT or CFT shorter and/or MCF, MaxV or AUC higher than in the 
healthy controls. 
 
 
3.9 Impedance aggregometry (MULTIPLATE®) 
Aggregometry impedance measure in WB was performed on the Multiplate® function 
analyser. [88] Test cells of this device incorporate a duplicate sensor for acceptance 
sampling and the results, given as Area Under the aggregation Curve (AUC, AU*min), 
are calculated as the mean values of the two curves. The platelets, after activation by 
different agonists, adhere to the two copper wires of each of the two independent 
measuring units. During analysis, the instrument continuously measures the changes of 
the electrical resistance (called “impedance”) between the electrodes that is proportional 
to the amount of platelets adhering to each couple of electrodes. Platelets were stimulated 
in three different ways: i) using TRAP-6 via the thrombin receptor (TRAP test - Roche 
Diagnostics GmbH, Mannheim, Germany); ii) via arachidonic acid, checking 
cyclooxygenase-dependent aggregation (ASPI test - Roche Diagnostics GmbH, 
Mannheim, Germany). This test is sensitive to acetylsalicylic acid, non-steroidal anti-
inflammatory drugs or other inhibitors of platelet cyclooxygenase; iii) using ADP via the 
ADP receptor (ADP test - Roche Diagnostics GmbH, Mannheim, Germany). 
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3.10 Statistical analysis 
3.10.1 Hypercoagulability detected by MP and thrombin generation 
Continuous variables were investigated for normality using the Shapiro-Wilk test. 
Normally distributed variables were summarized as mean (± SD) and Student’s t-test was 
performed, whereas non normally distributed variables were summarized as medians with 
interquartile ranges (IQR) and Mann-Whitney U-test was conducted. Bonferroni 
corrections were used to correct for multiple comparisons. Frequencies were provided for 
all nominal values and differences were calculated using Chi-square test. Pearson’s 
correlation analysis was used to detect significant correlations between MP numbers, ETP 
and metabolic, inflammatory and coagulation parameters. Multivariate regression analysis 
was used to examine the associations of MP subtypes with BMI and components of 
metabolic syndrome with models that adjusted simultaneously for several variables 
selected a priori, specifically: age, sex, physical activity and statin/antihypertensive 
medication use. Intraassay variability was determined by evaluating 20 random plasma 
samples 10 times within the same assay run (AMP numbers by flow-cytometry, PPL, TG 
assays) [%CV=(s/mean)*100, where CV= coefficient of variation]. Inter-assay variability 
was determined by evaluating the 20 random plasma samples in 10 consecutive assay 
runs [%CV=(s/mean)*100]. Data were analyzed by using PASW Statistics 17.0.2 (SPSS 
Inc., Chicago, IL, USA). A p-value of < 0.05 was considered significant. 
3.10.2 Hypercoagulability detected by ROTEM® and MULTIPLATE® 
The sample size calculation was based on pilot observations and the following 
assumptions: i) Expected increase in MCF of ≥ 3 mm; ii) Expected SD of 4.0mm (1); iii) 
power = 95%; iv) alpha = 0.05. Based on these assumptions we needed a group of at least 
42 obese patients. Continuous variables were investigated for normality using the 
Shapiro-Wilk test. Normally distributed variables were summarized as mean (±SD) and 
Student’s t-test was performed, whereas non normally distributed variables were 
summarized as medians with interquartile ranges (IQR) and Mann-Whitney U-test was 
conducted. Bonferroni corrections were used to correct for multiple comparisons. 
Pearson’s correlation analysis was used to detect significant associations between the 
parameters analyzed. A “p” value 0.05 was considered statistically significant. Statistical 
analysis was performed using the PASW Statistics 17.0.2 (SPSS Inc.) for Windows. 
 
3.10.3 MP after weight loss 
Continuous variables were investigated for normality using the Shapiro–Wilk test. 
52 
 
Normally distributed variables were summarized as mean (±SD) and Student’s t test was 
performed, whereas non normally distributed variables were summarized as medians with 
interquartile ranges (IQR) and Mann-Whitney U-test or Kruskall-Wallis test for multiple 
comparisons were conducted. Percentages of variation in variables were calculated as 
differences in values between after and before intervention and, divided by the values 
before the intervention. Spearman’s correlation analysis was used to detect significant 
correlations between MP and other parameters. The Bonferroni post hoc test was applied. 
Statistical significance was accepted at p\0.05, and SPSS ver. 22 was used. 
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4. RISULTS 
4.1. Metabolic and anthropometric parameters 
The anthropometric and metabolic characteristics of the study population are shown in 
Table 20. Patients had significantly higher HOMA-IR than controls. Patients with II and 
III degree of obesity had significantly lower mean levels of HDL and higher mean levels 
of triglycerides than controls. A similar worsening effect of the increase in BMI on 
atherogenic dyslipidaemia was also noted in overweight patients even if it was not 
statistically significant. Twenty-two obese patients (36%) were taking antihypertensive 
therapy (7 with I degree, 4 with II degree, and 11 with III degree): 10 patients were taking 
an angiotensin-converting enzyme (ACE) inhibitor, nine an angiotensin receptor blocker 
(ARB), and three a beta-blocker. Four overweight patients (20%) (2 ACE-inhibitors and 2 
ARBs) and five controls (12.5%) (2 ACE-inhibitors, 2 ARBs and 1 beta-blocker) were 
taking antihypertensive drugs. Thirteen obese patients (21%), two (10%) overweight 
subjects and three (7%) controls were taking statins. The dietary habits and physical 
activity did not differ significantly between cases and controls in the seven days prior to 
admission to the study. Thirtyfive (44%) obese patients had metabolic syndrome (7 in I 
degree obesity group, 14 in II and 14 in III degree obesity group). Categorization 
according to the different components of the metabolic syndrome was reported in Table 1. 
 
 
 
 
Controls 
(N = 40) 
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
Anthropometric parameters 
Age (years) 49 ± 14 45 ± 13 44 ± 15 41 ± 12 43 ± 12  
Male sex (No - %) 20 (50) 10 (50) 10 (50) 10 (50) 10 (50) 
BMI (kg/m
2
) 22.2 
± 1.55 
27.8 
± 1.09* 
32.2 
± 1.06
**
 
36.9  
± 1.60*** 
47.5  
± 6.84*** 
Waist (cm) 84.2 
± 4.4 
98.8  
± 4.8* 
105.4  
± 8.0**
 
120.0  
± 7.4*** 
138  
± 19.2*** 
Metabolic parameters  
Systolic blood 
pressure (mmHg) 
118 ± 5 131 ± 8 132 ± 13* 142 ± 17** 141 ± 16** 
Diastolic blood 
pressure (mmHg) 
77 ± 5 84 ± 10* 88 ± 11* 90 ± 8* 92 ± 13* 
Antihypertensive 
therapy, (N - %) 
5 (12.5) 4 (20) 7 (35)* 4 (20) 11 (55)*** 
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Controls 
(N = 40) 
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
HDL cholesterol 
(mg/dL) 
64 ± 20 58 ± 30 48 ± 13 45 ± 9
*
 44 ± 10
*
 
LDL colesterol 
(mg/dL) 
103 ± 38 116 ± 35 126 ± 31 119 ± 28 120 ± 31 
Triglycerides 
(mg/dL) 
79 ± 25 103 ± 58 100 ± 37 122 ± 32
*
 120 ± 47
*
 
Statins (N - %) 3 (7) 2 (10) 3 (15)* 5 (25)** 5 (25)** 
Fasting glucose 
(mg/dL) 
83  
[75-101] 
86  
[83-92] 
90  
[80-95] 
94  
[88-103]* 
94  
[87-100]* 
HOMA-IR 0.93 
[0.8-1.1] 
1.35 
[0.9-1.6]* 
2.0 
[1.02-
2.6]** 
2.16 
[1.0-2.7]** 
5.04 
[2.4-
6.4]*** 
Physical activity 
(min/week) 
120  
[30-190] 
100  
[30-180] 
90  
[30-150] 
90  
[20-120] 
90  
[20-120] 
Metabolic 
syndrome: n (%) 
- - 7 (35) 14 (70) 14 (70) 
Metabolic 
syndrome criteria: 
n (%) 
 
Waist - - 7/7 (100) 14/14 (100) 14/14 (100) 
Blood pressure - - 6/7 (85) 7/14 (50) 11/14 (78) 
Fasting glucose - - 2/7 (28) 3/14 (21) 4/14 (28) 
HDL cholesterol - - 5/7 (71) 12/14 (86) 12/14 (86) 
Triglycerides - - 2/7 (28) 6/14 (42) 7/14 (50) 
Data are expressed by mean ± standard deviation [SD] or median (interquartile range 
[IQR]). The Bonferroni adjusted significance level was 0.025 (0.05/2). p-values are 
expressed vs controls: *p < 0.025 **p < 0.01 ***p < 0.001.  
 
Table 1: Metabolic parameters. 
 
 
4.2. Inflammatory and coagulation parameters 
Obese patients presented with significantly higher mean levels of leptin and hs-CRP than 
healthy controls. A significant higher mean plasma level of IL-6 was observed only in III 
degree obese patients. There was no statistical difference in PT, PTT, platelet and white 
blood cells between cases and controls. Second and III degree obese patients had 
significantly higher levels of fibrinogen than controls. In I degree obese individuals the 
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fibrinogen was raised, compared to controls, but this difference was not statistically 
significant. No significant increase in FVIIa or FVIIa-AT complex was seen in any 
patient group compared to controls. All cases had significantly higher levels of FVIII than 
healthy individuals (Table 2). 
 
 
 
 
Controls 
(N = 40) 
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
IL-6  
(ng/L) 
2.0 
[1.1-2.3] 
2.1 
[1.5-2.5] 
2.4 
[1.4-2.7] 
2.4 
[1.9-2.7] 
2.6 
[2.4-3.1]
*
 
Leptin 
(ug/L) 
10 
[8.5-12] 
13 
[8.8-18] 
18 
[7.7-26]
*
 
24 
[11-30]
**
 
43 
[32-53]
**
 
TNFα  
(ng/L) 
6.1 
[5.5-7.1] 
7.6 
[5.6-8.5] 
7.4 
[5.8-8.5] 
7.5 
[6.6-8.3] 
8.9 
[7.5-10.3] 
hs-CRP  
(g/L) 
0.35  
[0.28-0.9] 
0.54  
[0.53-1.2] 
1.60  
[1.15-2.9]
*
 
2.61  
[1.52-4.45]
**
 
7.43  
[5.21-
16]
***
 
PT (%) 96 [87-105] 95 [81-109] 95 [75-115] 96 [81-112] 94 [85-
103] 
PTT (sec) 29 [25-33] 26 [22-30] 28 [25-32] 24 [20-28] 25 [17-33] 
White blood 
cells (x10
9
/L) 
6.1 ± 1.08 5.83 ± 0.96 6.85 ± 1.70 7.11 ± 2.25 7.27 ± 1.68 
Plateles 
(x10
9
/L ) 
227 ± 46 237 ± 45 249 ± 57 270 ± 62 265 ± 63 
Fibrinogen 
(mg/dL) 
288 
[249-360] 
283 
[271-330] 
328 
[302-353] 
348 
[299-444]
*
 
365 
[332-464]
**
 
FVIII (%) 78  
[64-92] 
84  
[66-105] 
109  
[87-137]
*
 
128  
[99-162]
**
 
139  
[90-173]** 
AT (%) 90 
[66-121] 
92  
[80-112] 
100  
[78-116] 
102  
[82-127]
*
 
105  
[84-129]
*
 
FVIIa (%) 74 [58-102] 86 [62-92] 81 [59-92] 81 [58-101] 93 [60-
110] 
FVIIa-AT (pM) 81 [80-98] 89 [76-110] 92 [82-113] 92 [81-118] 98 [84-
112] 
Data are expressed by mean ± standard deviation [SD] or median (interquartile range 
[IQR]). The Bonferroni adjusted significance level was 0.025 (0.05/2). p-values are 
expressed vs controls: *p < 0.025 **p < 0.01 ***p < 0.001.  
 
Table 2: Inflammatory and coagulation parameters.  
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4.3. Microparticles 
Table 3 shows the median and interquartile range (IQR) of the circulating MP levels in 
cases and controls. Significantly increased levels of AMP, LMP, TF+ were seen in 
overweight patients compared with controls (p < 0.025). Overall, significantly increased 
levels of all types of MP measured were seen in obese patients (p < 0.01) compared to 
controls. AMP, PMP, EMP and P-selectin + were markedly higher in II and III degree 
obese patients than in I degree (p < 0.001) and overweight patients (p < 0.001). LMP 
were similarly higher in overweight (p < 0.001 vs controls and p> 0.05 vs obese subjects) 
and obese patients (p < 0.001 for all comparisons) as compared with controls, with the 
highest levels in III degree obese subjects. Moreover, II and III degree obese had 
significantly higher AMP, PMP, EMP, P-selectin+ and LMP than I degree obesity (p < 
0.001 for all the comparisons, p < 0.01 for EMP). TF+ MP were significantly higher in 
overweight and obese patients compared with controls (p < 0.001 for all comparisons). 
There was no significant difference in TF+MP levels between overweight and obese 
individuals and between I degree obese and II-III degree obese subjects. Finally, III 
degree did not show increased levels of MP compared with II degree obesity. In the intra- 
and inter-assay analyses the enumeration of AMP by flow-cytometry in the 20 samples 
tested had CV 8% and 10%, respectively.  
PPL clotting time was significantly shorter (p < 0.01) in overweight and obese patients 
compared with controls; the shortest clotting time was found in II and III degree obese 
subjects. There were no differences in PPL between overweight and obese subjects. In the 
intra - and inter-assay analyses the 20 samples tested with PPL assay had CV < 10 % for 
both analyses (Table 3). 
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Controls 
(N = 40) 
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
AMP (N/µl) 1728 
[782-
2122] 
2391 
[1937-
2733]* 
2296 
[2157-
2635]** 
4029 
[3061-
5241]*** 
4976 
[3242-
6202]*** 
PMP 364 
[229-529] 
399 
[381-430] 
715 
[602-
883]*** 
3120 
[2867-
3420]**** 
3228 
[1782-
4112]**** 
P-Selectin+ 
MP 
544 
[450-602] 
595 
[537-632] 
1193 
[985-
2252]*** 
2014 
[1997-
2340]*** 
2134 
[1603-
3073]*** 
EMP 97 
[81-127] 
129 
[119-149] 
191 
[160-
220]*** 
239 
[209-291]*** 
234 
[176-290]*** 
LMP 95 
[87-117] 
276 
[227-
299]*** 
203 
[173-
313]*** 
299 
[271-334]*** 
375 
[251-448]*** 
MP-TF+ 31 
[17-83] 
161 
[149-
188]*** 
184 
[129-
206]*** 
167 
[149-234]*** 
180 
[153-222]*** 
PPL (sec.) 71 
[61-75] 
64 
[39-75]** 
57 
[49-75]*** 
44 
[40-60]*** 
46 
[40-64]*** 
Data are expressed by median and interquartile range (IQR). The Bonferroni adjusted 
significance level was 0.025 (0.05/2). p-values are expressed vs controls: *p < 0.02 **p < 
0.01 ***p < 0.001 ****p < 0.0001. 
 
Table 3: Circulating levels of different MP subtype in the study population. 
 
 
4.4. Thrombin generation 
The median and IQR lag-time, peak thrombin and ETP found in overweight and obese 
patients compared with controls are shown in Table 4. TG test results showed that obese 
patients had a significantly shorter mean lag time (p < 0.025), higher mean peak thrombin 
(p < 0.01) and increased mean ETP (p < 0.001) compared to healthy controls. Similar 
trends were seen in overweight patients though only the increase in ETP reached 
significance (p < 0.025). Additionally, overall obese patients showed significantly higher 
median ETP than overweight patients (p = 0.004), and II and III degree obesity patients 
had higher ETP than I degree obesity patients, but the difference was not statistically 
significant, after Bonferroni correction (p = 0.036). 
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Controls 
(N = 40) 
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
Lag Time  
(min) 
2.98 
[2.17-
4.17] 
2.83 
[2.25-3.17] 
2.50 
[2.50-3.17]
*
 
2.50 
[2.17-2,83]
*
 
2.45 
[1.83-2.83]
**
 
Peak 
thrombin 
(nM) 
276 
[178-288] 
306 
[219-361] 
317 
[292-372]
*
 
323 
[232-394]
*
 
371 
[335-404]
**
 
ETP  
(nM/min) 
1437 
[1235-
1526] 
1714 
[1448-1829]
*
 
1617 
[1452-1938]
*
 
1904 
[1507-
2078]
**
 
2103 
[1972-
2400]
***
 
Data are expressed by median and interquartile range (IQR). The Bonferroni adjusted 
significance level was 0.025 (0.05/2). p-values are expressed vs controls: *p < 0.02 **p < 
0.01 ***p < 0.001.  
 
Table 4: Comparison of thrombin generation test parameters between cases and controls. 
 
 
4.5. Correlation between TG and MP levels with anthropometric, inflammatory and 
coagulation parameters 
AMP, PMP and ETP positively correlated (p < 0.001) with BMI (r = 0.51, 0.81 and 0.68, 
respectively) and waist circumference (r = 0.50, 0.79 and 0.66, respectively) and with hs-
CRP (p < 0.001) (r = 0.46, 0.73, and 0.57, respectively) and leptin (p < 0.001) (r = 0.35, 
0.64 and 0.52, respectively). AMP and PMP showed a significant correlation with ETP (p 
< 0.001) (r = 0.39 and 0.45, respectively). PMP positively correlated with IL-6 (r = 0.37, 
p = 0.0007), platelet and white blood cells count (r = 0.58, p = 0.004 and r = 0.73, p = 
0.007, respectively). In the overall study population, the number of total MP, measured 
using annexin V (AMP) shows an inverse correlation with PPL (r = - 0.43, p = 0.0002). 
PMP inversely correlated with PPL (r = – 0.35, p = 0.003) and HDL (r = - 0.39, p < 
0.001). P-selectin+ MP showed a similar pattern but also positively correlated with TNF 
(r = 0.35, p < 0.001). EMP showed a similar pattern to P-selectin+, but they also 
correlated positively with FVIII and Fibrinogen (r = 0.37, p < 0.01 and r = 0.40, p < 
0.001, respectively). Finally, TF+MP and LMP showed the same pattern as EMP and they 
also correlated with white blood cells count (Table 5). 
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 AMP PMP P-
selectin+ 
MP 
EMP LMP  
TF+MP 
ETP 
 r p r p r p r p r p r p 
BMI 0.5
1 
<0.00
1 
0.8
1 
<0.00
1 
0.8
0 
<0.00
1 
0.6
9 
<0.00
1 
0.7
1 
0.00
1 
0.5
8 
<0.00
1 
Waist 0.5
0 
<0.00
1 
0.7
9 
<0.00
1 
0.7
0 
<0.00
1 
0.7
1 
<0.00
1 
0.6
5 
0.00
1 
0.6
6 
<0.00
1 
hs-CRP 0.4
6 
<0.00
1 
0.7
3 
<0.00
1 
ns ns ns 
0.5
7 
<0.00
1 
Leptin 0.3
5 
<0.00
1 
0.6
4 
<0.00
1 
ns ns ns 
0.5
2 
<0.00
1 
IL-6 ns 
0.3
7 
0.000
7 
ns ns 
0.4
5 
0.00
1 
ns 
TNF ns ns 
0.3
5 
<0.00
1 
0.4
2 
0.005 
0.5
0 
0.00
2 
ns 
WB cells ns 
0.7
3 
0.007 ns ns 
0.6
4 
0.00
1 
ns 
Platelets 
ns 
0.5
8 
0.004 ns ns ns ns 
ETP 0.3
9 
<0.00
1 
0.4
5 
<0.00
1 
ns ns ns - 
PPL -
0.4
3 
0.000
2 
-
0.3
5 
0.003 
-
0.4
1 
0.002 ns ns ns 
HDL 
ns 
-
0.3
9 
<0.00
1 
-
0.4
0 
<0.00
1 
ns ns ns 
Fibrinoge
n 
ns ns ns 
0.4
0 
<0.00
1 
0.4
9 
0.00
1 
ns 
FVIII 
ns ns ns 
0.3
7 
<0.01 
0.3
5 
0.00
1 
ns 
r expressed linear correlation (Pearson analysis).  
 
Table 5: Linear correlation between TG and MP levels with anthropometric, 
inflammatory and coagulation parameters. 
 
 
4.6 Correlation between MP levels/ETP and component of metabolic syndrome 
The 35 obese patients with metabolic syndrome did not show statistically significant 
higher MP levels and ETP than obese subjects without metabolic syndrome (data not 
shown). To investigate the impact of metabolic abnormalities associated with metabolic 
syndrome and BMI on MP subpopulation and ETP, a multivariate analysis, corrected for 
age, sex, physical activity and medication was performed (Table 6). In particular, in this 
multivariate model we showed that BMI and waist circumference were significantly 
correlated with all MP subtypes and with ETP. HDL significantly correlated with AMP 
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and PMP. The other components of metabolic syndrome did not correlated with MP and 
ETP. 
 
 AMP PMP EMP LMP MP-TF+ ETP 
 beta p beta p beta p bet
a 
p beta p bet
a 
p 
Waist 0.28 <0.00
1 
0.45 0.0
1 
0.14 0.0
4 
0.2
3 
0.0
2 
0.19 0.04 0.3
4 
<0.01 
Systolic 
BP 
0.09
8 
0.1 0.08 ns 0.07 ns 0.0
4 
ns 0.07 ns 0.0
2 
ns 
Diastolic 
BP 
0.06
0 
0.5 0.02 ns 0.03 ns 0.0
5 
ns 0.05
4 
ns 0.0
2 
ns 
Glycaemia 0.08
2 
0.20 0.01 ns 0.04 ns 0.0
3 
ns 0.03 ns 0.0
6 
ns 
HDL -
0.20 
<0.00
1 
-
0.29 
0.0
1 
-
0.02 
ns -
0.0
5 
ns -
0.09 
ns -
0.0
1 
ns 
Tryglicerid
es 
0.02
7 
ns 0.06
2 
ns 0.06
0 
ns 0.0
7 
ns 0.09 ns 0.0
3 
ns 
BMI 0.30
1 
<0.00
1 
0.25 0.0
1 
0.26 0.0
3 
0.1
6 
0.0
2 
0.24 <00
1 
0.3
7 
<0.00
1 
For regression multivariate model age, gender, physical activity and medication use were 
included as independent variables.  
 
Table 6: Multiple linear regression models predicting the number of different types of MP 
and ETP. 
 
 
4.7 Thromboelastogram Parameters 
CT in EXTEM was significantly shorter in II and III degree obese subjects than in 
controls. MCF, and AUC, both in INTEM and EXTEM, were significantly higher in II 
and III degree obese compared with controls. MCF in FIBTEM was significantly 
increased in I, II and III degree obesity 
than in healthy controls (Table 7). A representative figure of the ROTEM® profile from 
an III degree obese patient and a normal weight control sample is showed in Figure. 1.  
A significant linear correlation between MCF in FIBTEM with BMI (r = 0.62, p = 0.019) 
and waist circumference (r = 0.69, p = 0.006) and between MCF in FIBTEM with leptin, 
hs-CRP and fibrinogen levels (r = 0.61, p < 0.001, r = 0.78, p < 0.001 and r 0 0.40, p < 
0.001, respectively) was observed (Table 9). 
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Figure 1. Representative ROTEM® profile from a III degree obese subject and a normal 
weight control. A. INTEM, EXTEM and FIBTEM of a III degree obese subject. B. 
INTEM, EXTEM and FIBTEM of a normal weight subject. 
 
 
Data are expressed by mean ± SD. Bonferroni adjusted signiﬁcance level was 0.025 
(0.05/2). p are expressed vs controls: *p < 0.025 **p < 0.01 ***p < 0.00. 
Table 7. ROTEM® parameters. 
 Controls 
(N = 40) 
Overweight  Obesity  
(N = 20) I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
INTEM  
Ct (s) 177 ± 9 180 ± 33 185 ± 23 164 ± 22 177 ± 35 
CFT (s) 67 ± 16 61 ± 13 66 ± 15 60 ± 19 55 ± 15 
MCF (mm) 64 ± 5 66 ± 7 63 ± 5 67 ± 6 70 ± 4
***
 
MaxV (mm/min) 21 ± 5 22 ± 5 21 ± 6 24 ± 5 26 ± 5 
AUC 6333 ± 473 6426 ± 390 3677 ± 406 6797 ± 458
***
 6954 ± 
414
***
 
EXTEM  
Ct (s) 57 ± 11  51 ± 14 60 ± 11 47 ± 8
*
 49 ± 13
*
 
CFT (s) 74 ± 24 68 ± 15 76 ± 12 64 ± 16 61 ± 16 
MCF (mm) 65 ± 5 67 ± 5 66 ± 5 69 ± 4 71± 4
*
 
MaxV (mm/min) 19 ± 5 19 ± 5 19 ± 4 21 ± 5 22 ± 5 
AUC 6365 ± 497 6610 ± 460 6530 ± 430 6802 ± 381
**
 6973 ± 398
**
 
FIBTEM  
AUC  16 ± 5 20 ± 6 22 ± 5
*
 35 ± 7
**
 27 ± 10
**
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4.8 Whole Blood Aggregometry Parameters 
A statistically significant increase in platelet aggregation was seen between III degree 
obese subjects and normal weight controls for all the agonists used (Table 8). No 
difference was found between the other subgroup of cases and controls for the three 
agonists considered. A significant linear correlation between a) BMI with ADP and ASPI 
test (r = 0.79, p < 0.0001 and r = 0.70, p < 0.001, respectively); b) waist circumference 
with ADP and ASPI (r = 0.62, p < 0.001 and r = 0.57, p < 0.0001, respectively); c) leptin 
levels with ADP and ASPI (r = 0.41, p = 0.014 and r = 0.52, p < 0.001, respectively); d) 
hs-CRP with ADP and ASPI (r = 0.45, p = 0.001 and r = 0.55, p = 0.017, respectively); e) 
fibrinogen levels with ADP and ASPI (r = 0.49, p = 0.001 and r = 0.62, p < 0.001, 
respectively) was found. 
 
 Controls  
(N = 40)  
Overweight 
(N = 20) 
Obesity  
I degree 
(N = 20) 
II degree 
(N = 20) 
III degree 
(N = 20) 
TRAP 
(AUC) 
83 ± 20 84 ± 12 90 ± 15 90 ± 22 101 ± 23* 
ADP (AUC) 55 ± 8 54 ± 16 56 ± 21 63 ± 17 67 ± 18* 
ASPI (AUC) 47 ± 15 41 ± 15 49 ±17 58 ± 17 58 ± 15* 
Data are expressed by mean ± SD. Bonferroni adjusted significance level was 0.025 
(0.05/2). p are expressed vs controls: *p < 0.025. 
 
Table 8. Multiplate® parameters in the study population. 
 
 INTEM-
MCF 
EXTEM-
MCF 
FIBTEM-
MCF 
ADP ASPI 
 r p r p r p r p r p 
Age  0.26 0.011 0.22 0.035 0.31 0.011 ns ns 
BMI ns 0.44 <0.011 0.62 0.019 0.79 <0.001 0.70 <0.001 
Waist  ns 0.51 <0.001 0.69 0.006 0.62 <0.001 0.57 <0.001 
Platelet 
count  
ns ns ns 0.47 0.001 0.40 0.0011 
Leptin ns ns 0.61 <0.001 0.41 0.014 0.52 <0.001 
Hs-CRP ns ns 0.78 <0.001 0.45 0.001 0.55 0.017 
Fibrinogen  ns ns 0.40 <0.001 0.49 0.001 0.62 <0.001 
 
Table 9. Correlations between laboratory and clinical parameters. 
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4.9 ROTEM® and aggregometry parameters and metabolic syndrome 
The 35 obese patients with metabolic syndrome did not show statistically significant 
difference in ROTEM® and aggregometry parameters compared with the 45 obese 
subjects without metabolic syndrome. In particular, patients with metabolic syndrome 
showed higher MCF in INTEM (71 ± 6 mm), EXTEM (68 ± 5 mm) and FIBTEM (23 ± 6 
mm) than obese subjects without metabolic syndrome (69 ± 5, 67 ± 3 and 21 ± 5 mm, 
respectively), but the difference was not statistically different (p > 0.05 for all 
comparisons). Obese with metabolic syndrome had higher TRAP (92 ± 18 AUC), ADP 
(59 ± 7 AUC) and ASPI (52 ± 12 AUC) than patients without metabolic syndrome (90 ± 
20, 56 ± 8 and 49 ± 17 AUC, respectively) without statistically significant difference (p > 
0.05). 
 
 
4.10 Clinical characteristics and metabolic, laboratory and inflammatory 
parameters after weight loss  
The anthropometric and metabolic characteristics of the study population are shown in 
Table 10. Obese patients had a significantly higher mean BMI and waist circumference at 
baseline (T0) than 3 months (T3) and 12 months (T12) after SLG. Obese patients had a 
reduction of 18% of BMI at T3 and of 41% at T12; there was a reduction of 29% of the 
BMI at T12 compared with T3. Moreover, obese patients had a significant reduction of 
triglycerides, basal insulin, glucose and HOMA, and a significant increase of HDL at T12 
compared with T0. There was no statistical difference in platelet and white blood cells 
counts between obese patients at T0 and T12. Obese patients showed a meaningful 
reduction of TNF, leptin and hs-CRP at T12 compared with T0 (Table 11). 
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 Baseline  
(N = 20)  
3 months after 
SLG (N=20) 
12 months after SLG 
(N=20) 
 % of 
variation 
p versus 
baseline 
 % of 
variation 
p versus 
baseline 
Anthropometric 
characteristis  
       
Age (years) 43 ± 12 - - - - - - 
Male sex-no (%) 10 (50) - - - - - - 
BMI (kg/m
2
) 47.5 ± 
6.9 
40.3 
± 7.4 
-18 ±6 0.001 34.8 
± 7.3 
-41 ±10 <0.001 
Metabolic 
parameters 
       
Systolic blood 
pressure (mmHg) 
141 
± 16 
130 
± 11 
-12  
±3 
ns 129 
± 12 
-13 
 ± 9 
ns 
Diastolic blood 
pressure (mmHg)  
92 ± 13 83 ± 
7 
-10 ± 6 ns 85 ± 
8 
-9 ± 5 ns 
Total cholesterol 
(mg/dl) 
197 ± 32    176 
±26 
-7 ± 3 ns 
HDL (mg/dl) 44 ± 10    56 ± 
17 
25 ± 5.3 0.04 
LDL (mg/dl) 120 ± 31    102 ± 
23 
-12 ± 7.2 ns 
Tryglicerides 
(mg/dl) 
120 ± 47    80 ± 
28 
- 21 ± 10 0.002 
Insulin (mU/l) 14 
[12-22] 
   9 
[4-
11] 
-4 ± 3.3 0.019 
Fasting glucose 
(mg/dl) 
94 
[87-100] 
   82 
[76-
87] 
-12 ± 7 0.008 
HOMA-IR 5.0 
[2.4-6.4] 
   1.78 
[0.8-
2-1] 
-20 ± 5.1 0.007 
Data are expressed by mean ± standard deviation (SD) or median and range interquartile 
(IQR).  
 
Table 10. Anthropometric and metabolic characteristics of obese patients at baseline, 3 
and 12 months after sleeve gastrectomy (SLG) 
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 T0  
(N=20) 
T12 
(N = 20) 
  
% of variation p 
White blood cells (x10
9
/L) 7.27 ± 1.6 6.23 ± 1.40 -9 ± 2 ns 
Platelets (x10
9
/L) 265 ± 63 275 ± 68 3 ± 2 ns 
TNF 9 ± 1.6 7.1 ± 2.6 - 18 ± 9 0.027 
IL-6 3.2 ± 1.8 2.3 ± 0.7 -14 ± 10 0.056 
Leptin 46.4 ± 16.5 21.7 ± 16.3 -53 ± 27 < 0.001 
Hs-CRP 10.71 ± 8.40 4.21 ± 3.61 -20 ± 14 0.008 
Data are expressed by mean ± standard deviation. 
 
Table 11. Laboratory and inflammatory parameters of obese patients at baseline (T0) and 
12 months after sleeve gastrectomy (T12). 
 
 
4.11 Microparticles plasma levels after weight loss 
Figure 12 shows the median and interquartile range (IQR) of the circulating MP levels in 
III degree obese patients before and after weight loss. Significantly increased levels of 
Annexin V-MP, platelet-derived MP (both CD61+ and P-Selectin+), leukocyte-derived 
MP, TF+MP and CD36+MP were detected in obese patients at T0 compared with obese 
patients 3 months after SLG (T3). On the contrary, no statistically significant difference 
was detected in endothelial-derived MP at T0 compared with T3. Furthermore, obese 
patients at T0 showed significantly higher levels of all types of MP measured compared 
with T12 (see Fig. 2). Finally, subjects at T12 showed higher median levels of all types of 
MP, except endothelial-derived MP, compared with T3 but the differences were not 
statistically significant. Levels of endothelial-derived MP were lower at T12 compared 
with T3, but the difference was not statistically significant. In Table 12 we show the 
reported percentages of reduction of the different subtypes of MP. 
Figure 2 (grey area) also reports the median plasma levels of MP previous found in a 
healthy lean population. In particular, obese subjects at T3 show significantly higher 
levels of Annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+), 
leukocyte-derived MP and TF+MP than healthy lean controls. They also show 
significantly higher levels of all MP subtypes at T12 compared with controls. 
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 % of variation 
 T0-T3 p T0-T12 p T3-T12 p 
AMP - 30 ± 15 0.0015 - 16 ± 10 0.035 25 ± 12 ns 
EMP - 9 ± 14 ns - 30 ± 23 0.009 -10 ± 4 ns 
PMP - 38 ± 20 < 0.0001 - 27 ± 16 0.0062 20 ± 18  ns 
P-
selectin+MP 
- 9 ± 5 0.0036 - 26 ± 12 0.031 53 ± 45 ns 
LMP - 36 ± 16 < 0.0001 - 35 ± 18 0.0011 4 ± 3 ns 
TF+MP - 33 ± 19 < 0.0001 - 32 ± 27 0.0012 10 ± 2 ns 
CD36+ - 27 ±12 0.0011 - 33 ± 15 0.0044 24 ± 10 ns 
Data are expressed by mean ± standard deviation.  
 
Table 12. Percentage of reduction of all microparticles subtypes 3 and 12 months after 
sleeve gastrectomy (T3) and (T12). 
 
 
4.12 MP functional activity 
The PPL clotting time is significantly shorter in obese patients at T0–T3. There is no 
significant disparity in PPL clotting time between morbidly obese patients at T0 and T12, 
and between individuals at T3 and T12 (Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
Phospholipid-dependent clotting time in III degree obese patients at baseline, 3 and 12 
months after sleeve gastrectomy. Data are expressed by median and interquartile range; p 
are calculated versus basal. *p < 0.05 
 
Figure 3. PPL clotting time. 
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4.13 Correlation between weight reduction and microparticles 
The correlations among percentages of reduction in MP levels, anthropometric and 
inflammatory parameters before and 12 months after SLG are shown in Table 13. There is 
a statistically significant positive correlation between percentages of reduction in all MP 
considered with percentages of reduction in BMI. A significant positive correlation exists 
between the reduction of leukocyte-derived MP and leptin reduction, TF+MP reduction 
and hs-CRP reduction, and between CD36-MP reduction and waist circumference, hs-
CRP and leptin reduction. 
 
 
AMP EMP 
P-
selectin+M
P 
LMP MP-TF+ CD36+ 
 r p r p r p r p r p r p 
BMI 0.3
8 
0.02
7 
0.46 
0.02
7 
0.42 0.022 
0.5
9 
0.00
2 
0.3
6 
0.036 
0.7
1 
<0.00
1 
Waist 0.5
0 
0.03
1 
0.08 ns 0.17 ns 
0.1
9 
ns 
0.0
4 
ns 
0.4
6 
0.01 
hs-
CRP 
0.3
2 
ns 0.02 ns 0.15 ns 
0.5
8 
ns 
0.8
0 
0.000
3 
0.8
1 
<0.00
1 
TNF
 
0.2
0 
ns 0.01 ns 0.04 ns 
0.0
1 
ns 
0.3
8 
ns 
0.0
1 
ns 
IL-6 
0.4
1 
ns -0.29 ns 
-
0.02 
ns 
-
0.1
6 
ns 
-
0.0
4 
ns 
0.2
5 
ns 
Lepti
n 
0.2
6 
ns 
0.06
2 
ns 0.06 ns 
0.5
4 
0.03
2 
0.5
2 
0.041 
0.5
7 
0.034 
BMI: body mass index, MP: microparticles, IL: interleukin, hs-CRP: high sensitive C 
reactive protein, TF: tissue factor. 
 
Table 13. Correlations between percentages of reduction of microparticles and 
percentages of reductions of anthropometric and inflammatory parameters 
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5 DISCUSSION 
Obesity is often associated with alterations in the coagulation factor levels predisposing to 
hypercoagulability. In this case-control study of 20 overweight and 60 obese subjects 
presented a prothrombotic state compared with normal weight controls and 
hypercoagulability was demonstrated with tests that consider hemostasis in a holistic 
manner.  
Different subpopulations of circulating MP (Annexin V+, endothelial-, platelet-, P-
selectin+, leukocyte-derived and TF+) were found to be significantly higher compared 
with normal weight healthy controls. The phospholipid procoagulant activity was 
increased in overweight and obese patients than in controls. The levels of all subtypes of 
MP increased progressively with the severity of obesity and this trend was also observed 
in overweight subjects free of metabolic syndrome for EMP, LMP and TF+MP. 
Moreover, thrombin generation tests confirmed this prothrombotic profile: obese subjects 
had significantly shorter lag time and increased peak thrombin and ETP levels compared 
with lean subjects. A similar trend was seen in overweight patients but this difference 
only reached significance for ETP. Finally, no difference in the level of FVIIa-AT 
complex levels could be seen between the patient groups and the normal subjects. 
Similarly, the whole blood thromboelastometry profiles in subjects with III degree obesity 
were consistent with a prothrombotic state characterized both by an acceleration of the 
propagation phase of blood clot formation (i.e., reduction of CT and CFT in EXTEM) and 
a higher clot strength (i.e., increase in MCF and AUC in INTEM, EXTEM and FIBTEM). 
Indeed, the shortening of CT in EXTEM detected in II and III degree of obesity could be 
explained by an enhanced tissue factor-driven thrombin generation capability. As far as 
the whole blood aggregometry was concerned, III degree obesity subjects showed 
hyperaggregability in all the three tests (i.e., TRAP, ADP and ASPI) performed. 
Moreover, a significant correlation between BMI and waist circumference and ADP/ASPI 
tests was found.  
 
It’s known that PMP levels are significantly elevated in obese non-diabetic subjects in 
comparison to non-obese subjects, and the values correlated with BMI, waist 
circumference, fat tissue mass; significant reductions in PMP levels were observed after 
weight loss. In our study we described the presence of increased concentrations of PMP 
and P-selectin+ MP in subjects with obesity. P-selectin is a cell-adhesion molecule that 
translocates from alpha-granules to the platelet surface upon activation. In controls, 
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overweight and I degree obese patients we observed higher levels of P-selectin+ than 
PMP. Probably P-selectin+ MP contribute to the development of early stage vascular 
dysfunction by facilitating the initial recruitment of leukocytes, LMP and platelets to the 
endothelium. A variety of platelet function abnormalities, including increased 
adhesiveness and activation in vitro and in vivo and reduced sensitivity to physiological 
agonists, has been characterized in obese subjects.[109] Moreover, it’s known that obese 
subjects have greater native platelet reactivity measured by dual-channel 
lumiaggregometer in platelet-reach plasma. [64, 110] 
In this study we also described a significant difference in platelet aggregation between III 
degree obese patients and healthy controls in whole blood multiple impedance 
aggregometry tests. Indeed, a significant correlation between aggregometry parameters 
with BMI, waist circumference, leptin levels and hs-CRP was also found. 
Proinflammatory adipokines have also a role in enhancing platelets aggregating 
responses. As previously showed by Corsonello et al. [96], leptin produces a dose-
dependent enhancement of ADP-induced platelet aggregation in healthy controls. The 
prothrombotic actions of leptin in vivo include enhanced agonist-induced platelet 
aggregation and increased stability of arterial thrombi. Leptin induces platelet aggregation 
by synergizing with subthreshold concentrations of agonists, in particular ADP and 
thrombin (TRAP test).[95, 109] 
Moreover, the increased oxidative stress present in obesity leads to enhanced lipid 
peroxidation and free radical-catalyzed conversion of arachidonic acid into bioactive 
forms that are able to affect platelet functions such as adhesive reactions and activation by 
low concentrations of other agonists via cyclooxygenase-dependent aggregation.[109] 
These observations could explain our findings of increased platelets responses to 
Adenosine diphosphate (ADP), Thrombin activating peptide (TRAP) and Arachidonic 
Acid (ASPI) agonists in III degree obesity compared to healthy controls and the 
significant correlation between leptin and hs-CRP with ADP and ASPI aggregation 
capability.  
Finally, the presence of platelet activation in obesity is confirmed by the observation that 
plasmatic levels of circulating PMP and P-selectin+ MP are significantly elevated in 
obese subjects and by aggregometry tests. These findings suggest how platelet hyper-
reactivity/activation in obese patients can play a pivotal role for an accelerated risk of 
atherothrombosis.  
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Leukocyte-derived MP have been reported to be key factors in pathways activated by 
obesity-mediated inflammation. In this study, LMP were significantly higher in 
overweight and obese patients than in controls. Adipose tissue is a source of adipokines 
such as TNF, IL-6 and leptin, which influence systemic and vascular 
inflammation.[111] We observed a progressive increase in all inflammatory markers 
(TNF, IL-6, leptin and hs-CRP) consistent with the levels of obesity. These changes 
were only significant for IL-6 in III degree obesity and for leptin and hs-CRP according 
to the degrees of obesity. In our study, the levels of MP positively correlated with those of 
leptin and hs-CRP. As previously reported [46, 112], we found increased levels of FVIII 
and fibrinogen which are also likely to confirm the chronic inflammatory condition of the 
obese patients. LMP positively correlated with fibrinogen, FVIII and white blood cells 
count. Thus we confirmed that the majority of MP detected in these individuals was 
derived from platelets (PMP and P-selectin+) and leukocytes, and that they correlated 
with inflammatory marker.[64, 113] LMP were demonstrated to induce endothelial 
dysfunction, to favor the secretion of pro-inflammatory cytokines by activated endothelial 
cells and to promote the expression of TF.[113] It is well known that obese patients 
exhibit increased TF-mediated coagulation, with raised adipocyte and monocyte TF 
expression secondary to elevated CRP, leptin, TNF, TGFβ, angiotensin II and 
insulin.[111] We detected higher TF+ MP levels in overweight and obese patients than in 
controls, even in the absence of an increase in TF activation, as assessed by FVIIa-AT 
levels. TF+MP also positively correlated with TNF, fibrinogen, FVIII and white blood 
cells count. Thus, TF+MP may be induced by LMP and play a role in the global 
prothrombotic state. 
Our findings confirm the close relationship between obesity and hypercoagulability. The 
levels of proinflammatory adipokines increase with increasing adipose tissue, diminish 
after weight loss and have a procoagulant potential.[113] We also found that MCF in 
FIBTEM positively correlated with leptin and hs-CRP, thus confirming that 
prothrombotic and proinflammatory states may be metabolically interconnected. As a 
result of exposure to an inflammatory stimulus, circulating blood cells express tissue 
factor and PAI-1, fibrinogen release, and platelet activation leading to intravascular 
clotting, vessel occlusion, and thrombotic pathology. Fibrinogen, an acute-phase reactant 
like CRP, rises in response to a high cytokine state.[114] Elevated levels of several 
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coagulation factors (i.e. FVIII, FVII, and fibrinogen) often detected in obese patients [46] 
could partly explain the hypercoagulable profile seen by thromboelastometry. 
We detected significantly higher both fibrinogen levels and FIBTEM-MCF in II and III 
degree obese patients compared to normal weight controls, although fibrinogen level 
remained within the normal range. It has been recently well demonstrated that exist a 
good correlation between the fibrinogen level and the FIBTEM assay.[115, 116] 
Importantly, since FIBTEM is designed to measure elasticity of the fibrin clot under 
platelet inhibition by cytochalasin D.[117] FIBTEM MCF should not only be considered 
as a measurement of fibrinogen concentration, but also, mainly, a measurement of 
mechanical properties of the fibrin clot which are only in part related to fibrinogen 
concentration.[118] Thus we can state that in obese population there was increased fibrin 
monomer polymerization, as detected by high FIBTEM MCF, more than increase 
fibrinogen concentration (whose levels remained within the normal range). 
 
Obesity is often associated with metabolic syndrome. Circulating MP have been found to 
be associated with the cluster of abnormalities characteristic of metabolic syndrome.[119] 
In particular, obesity can induce the development of type 2 diabetes, a condition 
characterized by altered MP status. Zhang et al. described the presence of PMP and LMP 
in patient with type 2 diabetes independently to obesity.[120] Our study population 
comprises also 35 subjects affected by obesity without metabolic syndrome, therefore our 
results suggest that the hypercoagulable state linked to obesity starts independently. We 
found a positive correlation between BMI and waist circumference and circulating MP 
levels on the one hand and increased TG on the other, but not with the other components 
of metabolic syndrome, even after adjusting for medication, suggesting a tight association 
between prothrombotic potential and fat mass. Similarly, the 35 obese patients with 
metabolic syndrome did not show statistically significant difference in ROTEM® and 
aggregometry parameters compared with the 45 obese subjects without metabolic 
syndrome, but a significant correlation between FIBTEM-MCF and aggregometry 
parameters with BMI, waist circumference, leptin levels and high sensitive-C reactive 
proteins was also found. 
Our data suggest that the degree of hypercoagulability rises progressively as body weight 
increases from overweight to third degree obesity. EMP, LMP, TF+ MP and thrombin 
generation test, in particular ETP, are higher in overweight subjects than in healthy lean 
controls. Thus, the prothrombotic state is present in overweight individuals, even before 
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the appearance of insulin resistance (measured by HOMA-IR) and the complications of 
the disease, such as type II diabetes, atherogenic dyslipidemia, or metabolic syndrome. 
[121] Obesity can be considered a chronic, low-grade inflammatory state [111] in which 
altered metabolic signals emerging from adipocytes start the inflammatory responses and 
damage metabolic homeostasis.[122] 
A recent study, in a mouse model, showed that leptin and IL-6 levels were already 
increased in overweight mice and were further elevated in obese mice. Adipocyte size and 
number of adipose macrophage infiltrations showed a similar trend.[123] This pro-
inflammatory state, already present in overweight, may lead to a prothrombotic state 
indirectly by inducing oxidative stress and endothelial dysfunction. Thrombosis and 
inflammation are related and mutually reinforcing processes, involving inflammatory 
mediators (e. g. endotoxin, TNF, and CD40 ligand), tissue factor expression on 
monocytes and the activated endothelium, and circulating TF–bearing MP.[77] Notably, 
our data suggest that the hypercoagulability measured by increased release of EMP, LMP 
and TF-bearing MP and increased ETP may be the first sign of this chronic low-grade 
inflammation and microvascular dysfunction and may have a role in the management of 
patients who could benefit therapeutic interventions to inhibit inflammatory pathways. 
 
In order to evaluate the effect of weight loss on prothrombotic state, in a prospective 
study of 20 morbidly obese patients, different subpopulations of circulating MP (Annexin 
V+, endothelial-, platelet-, P-Selectin+, leukocyte-derived, TF+ and CD36+) were 
measured before, 3 and 12 months after sleeve gastrectomy. We find all MP, except 
endothelial-derived MP, significantly decreased 3 months after SLG when patients had 
lost 18% of body weight, and all MP subtypes significantly decreased 12 months after 
SLG when patients had lost 41% of body weight. All types of MP, except endothelial-
derived, show a partial upturn at 12 months compared with the 3 months measurement, 
even if patients had lost 29% of their initial body weight. Finally, all MP subtypes at T12 
remain significantly higher compared to the levels previously found in a healthy lean 
population.  
The levels of proinflammatory adipokines with a procoagulant potential increase in 
proportion to the amount of adipose tissue and diminish after weight loss.[122] Our 
results are in line with previous observations, in particular Murakami et al. [124] who 
show that weight reduction by either calorie restriction with or without exercise reduces 
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platelet-derived MP production, probably through reduction of adipose tissue. More 
recently, Morel et al. [113] show that a short-term very low-calorie diet and weight loss 
results in an overall improvement of the hemostatic balance characterized by the 
reduction of platelet and leukocyte-derived MP and a reduction in leptin levels in obese 
individuals. Also Cheng et al. [125] demonstrate that the reduction in microparticles after 
bariatric surgery in patients with type 2 diabetes reflects an attenuation of inflammation, 
and this mechanism may contribute to normalization of glycemic control. In our study we 
confirm an improvement of metabolic parameters (fasting glucose, insulin, HOMA and 
HDL cholesterol) and inflammatory parameters (TNF, IL-6, leptin and hs-CRP) 12 
months after SLG. We find that percentages of reduction of all MP considered are closely 
correlated with the percentage of reduction of BMI, confirming a very active role of the 
adipose tissue in the production of MP. However, only the reduction of leukocyte-
derived, TF+ and CD36+MP are significantly correlated with reduction of leptin, and the 
reduction of leukocyte-derived and CD36+MP is significantly correlated with hs-CRP 
decrease. The present study further confirms a role for leukocyte-derived MP and TF+MP 
as key factors in obesity mediated inflammation pathways. 
CD36 is a multifunctional signaling molecule with several known ligands, including 
thrombospondin-1, long chain fatty acids and both native and atherogenic lipoproteins, 
including oxidized low-density and high-density lipoproteins.[126] CD36 is expressed on 
a variety of cells and tissues, including platelets, erythrocytes, monocytes, endothelial 
cells and leucocytes. It is intimately involved in lipid metabolism and homoeostasis, and 
has been strongly implicated in pathological conditions associated with metabolic 
dysregulation, including obesity, insulin resistance, diabetes, diabetic nephropathy and 
atherosclerosis. Previous studies demonstrate that soluble CD36 in plasma is associated 
with circulating MP, and that CD36+MP levels are significantly higher in obese people 
with type 2 diabetes compared to controls. Here we also confirm the presence of 
CD36+MP in obese patients independently of diabetes, and an association with BMI, 
waist circumference, leptin and hs-CRP reduction. [78, 79] We find an overall slight 
increase in all MP subtypes (except endothelial-derived) at T12 compared with T3 
measurement, despite a further decrease in BMI. This may suggest a persistence of 
inflammatory responses, in which altered metabolic signals, probably emerging from 
adipocytes, reignite a low-grade inflammatory state, and slowly impair coagulation 
homeostasis. This might also be related to the median BMI at T12 (34.8 kg/m
2
) namely a 
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II degree obesity, which is correlated with a low grade chronic inflammation regardless of 
comorbidities. It would be useful to know the trend of the MP even years after bariatric 
surgery when the weight reaches stabilization. Finally, we have to comment on the trend 
of endothelial-derived MP that decrease at a slower rate than other MP subtypes, and 
keep decreasing from T3 to T12. It seems that the low-grade inflammatory response at 
T12 involves blood cells (mainly platelets and leukocytes) more than endothelial cells, 
and that this initial procoagulant-proinflammatory response does not determine any 
endothelial dysfunction.  
The strength of our study lies in the prospective evaluation of a cohort of consecutive 
patients with III degree obesity who have undergone the same sleeve gastrectomy 
procedure. Potential confounders were avoided by excluding subjects with conditions 
known to be associated with high levels of circulating MP. Since MP are an essential part 
of the physiological and pathological cellular remodelling, they mirror the turnover of 
different cell types in the circulation. From a clinical point of view, MP can be considered 
mediators in the cross-talk between inflammation and hemostasis, and they provide new 
prognostic opportunities and therapeutic approaches to attenuate prothrombotic 
complications by steering thromboprophylaxis or anti-inflammatory therapy. 
 
Our study suffers from some limitations. Firstly, the size of the study population is 
limited, mainly because we enrolled obese patients free from other pathological 
conditions potentially associated with prothrombotic state. We only collected 20 patients 
in each group. Nonetheless, we were able to detect significant differences between the 
groups but this needs to be validated by larger studies. Although it was well known that 
different dietary habits and physical exercise between cases and controls could influence 
coagulation parameters [127], we enrolled patients and controls with similar dietary 
habits and exercise in the five days prior to enrollment. 
Moreover, due to the cross-sectional design of the study, causality in the associations is 
not demonstrated and further research is needed in order to determine the mechanisms 
underlying the prothrombotic tendency detected. 
As for methods, it is also important to bear in mind that currently available methods for 
detection of MP are still suboptimal. Flow cytometric (FCT) assays may not be sensitive 
enough to detect all sizes of MP, given that many of these fall below the detection 
threshold, though recommendations by the ISTH SSC Working Group on Vascular 
Biology [106, 128] were used. It has been shown that the TG was associated with MP 
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smaller than 0.1 μM below the cut-off threshold of FCT. [129] Although these could be 
indirectly measured by both TG and PPL we would not have identified them by FCT.  
Second, we only considered MP expressing phosphatidylserine, but only a minority of 
circulating microvescicles expose phosphatidylserine.[130-132] Thus we could only 
account for a minority percentage of MP, and this may lead to interpretation bias. Despite 
these limitations, annexin V is considered a valuable marker of MP of different origins, 
with the advantages of having a relatively high density of the target molecules on MP and 
excellent reproducibility of measurements.[131]  
Third, with our current staining method, we can only account for a single cellular marker 
to detect the possible origin of the MP, thus inability to show the possible origin of TF+ 
or CD36+MP. A new model has been recently hypothesized where MP are complex 
ambivalent structures that express both activators and inhibitors of coagulation, and also 
convey fibrinolytic properties [133]. In this study, to better characterize the measurement 
of these MP, we also used a functional MP activity assay. The PPL clotting time assay 
precisely reflects the flow cytometry results. 
We only performed an indirect measure of the active TF levels, by using circulating TF-
bearing MP and FVIIa-AT complex, whether direct measurement of TF by ELISA assays 
mirrors the data obtained by FVIIa-AT complexes assays need to be confirmed. 
Moreover, the cellular origin of the TF+ MP was not investigated due to our FCT 
detection limit, so we could only account for TF+MP without qualifying the TF+ source. 
However, the co-labelling method between anti-TF antibody and others activation 
markers is not fully standardized. Finally, it has been recently hypothesized 
a new vision of MP [133] as complex ambivalent structures that express both activators 
and inhibitors of coagulation and also convey fibrinolytic properties. In our study we 
could only explore 
the presence of MP with procoagulant properties and no information is available on their 
potential fibrinolytic role. 
Moreover, we did not perform TG assay in the absence of both TF and phospholipids to 
further characterize the procoagulant potential of plasma and MP of patients with obesity, 
but this method is not standardized. It should also be noted that all MP and TG testing 
was performed on frozen samples, frozen and thawed prior to analysis, as is usual with 
these types of clinical studies. As MP may break down during storage at –80 °C and lose 
capacity to bind the anti-Annexin V antibody [130], care was taken to ensure that storage 
time of platelet-free plasmas was similar between groups. We cannot exclude that the 
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freezethawing cycle could also have had some influence on the TG and PPL assay. To 
eliminate any cellular contamination of the samples only double-spun plasma samples 
were used. The samples tested had only been frozen once and no repeat frozen and 
thawed samples were used. 
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6 CONCLUSION  
In conclusion, this study shows that a hypercoagulable state is already present in 
overweight patients and progressively increased in relation to the severity of obesity.  
Secondly, we found that the high levels of inflammatory markers, associated with an 
excessive amount of adipose tissue, may induce an overproduction of different types of 
procoagulant MP and an increase of thrombin generation and 
thromobelastometric/aggregometry parameters, thus confirming the emerging concept 
that hypercoagulability and inflammation are related and mutually reinforcing processes 
in obesity. 
In addition, the significant correlation between degree of obesity and multiple global 
prothrombrotic parameters suggests that hypercoagulability is associated with adipose 
tissue itself.  
Also the decrease of different MP after surgery weight loss is positively correlated with 
the decrease of BMI and waist rather than the ameliorated metabolic and flogistic state. 
Finally, hypercoagulability precedes the onset of metabolic syndrome and seems to be 
independent of insulin resistance.  
Further prospective work is needed to determine how these global hemostasis assays can 
be useful to identify a group of obese patients at increased arterial and thrombotic risk in 
driving the better anticoagulant prophylaxis/therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
7 BIBLIOGRAPHY 
Articles  
1. ADA timely statement on Nutrition and Your Health: Dietary Guidelines for 
Americans. J Am Diet Assoc, 1990. 90(12): p. 1720. 
2. Oliveros, E., et al., The concept of normal weight obesity. Prog Cardiovasc Dis, 
2014. 56(4): p. 426-33. 
3. Obesity: preventing and managing the global epidemic. Report of a WHO 
consultation. World Health Organ Tech Rep Ser, 2000. 894: p. i-xii, 1-253. 
4. Nuttall, F.Q., Body Mass Index: Obesity, BMI, and Health: A Critical Review. 
Nutr Today, 2015. 50(3): p. 117-128. 
5. National Task Force on the, P. and O. Treatment of, Overweight, obesity, and 
health risk. Arch Intern Med, 2000. 160(7): p. 898-904. 
6. Sowers, J.R., Obesity as a cardiovascular risk factor. Am J Med, 2003. 115 
Suppl 8A: p. 37S-41S. 
7. Jung, C.H., W.J. Lee, and K.H. Song, Metabolically healthy obesity: a friend or 
foe? Korean J Intern Med, 2017. 32(4): p. 611-621. 
8. Clinical guidelines on the identification, evaluation, and treatment of overweight 
and obesity in adults: executive summary. Expert Panel on the Identification, 
Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr, 1998. 68(4): 
p. 899-917. 
9. Ogden, C.L., et al., Prevalence of obesity among adults: United States, 2011-
2012. NCHS Data Brief, 2013(131): p. 1-8. 
10. Ng, M., et al., Global, regional, and national prevalence of overweight and 
obesity in children and adults during 1980-2013: a systematic analysis for the 
Global Burden of Disease Study 2013. Lancet, 2014. 384(9945): p. 766-81. 
11. Duranti, S., et al., Obesity and microbiota: an example of an intricate 
relationship. Genes Nutr, 2017. 12: p. 18. 
12. Kant, A.K. and B.I. Graubard, Secular trends in patterns of self-reported food 
consumption of adult Americans: NHANES 1971-1975 to NHANES 1999-2002. 
Am J Clin Nutr, 2006. 84(5): p. 1215-23. 
13. Prentice, A.M. and S.A. Jebb, Obesity in Britain: gluttony or sloth? BMJ, 1995. 
311(7002): p. 437-9. 
14. Dietz, W.H., Jr. and S.L. Gortmaker, Do we fatten our children at the television 
set? Obesity and television viewing in children and adolescents. Pediatrics, 1985. 
75(5): p. 807-12. 
15. Farooqi, I.S. and S. O'Rahilly, New advances in the genetics of early onset 
obesity. Int J Obes (Lond), 2005. 29(10): p. 1149-52. 
16. Whitaker, R.C., et al., Predicting obesity in young adulthood from childhood and 
parental obesity. N Engl J Med, 1997. 337(13): p. 869-73. 
17. Neel, J.V., Diabetes mellitus: a "thrifty" genotype rendered detrimental by 
"progress"? 1962. Bull World Health Organ, 1999. 77(8): p. 694-703; discussion 
692-3. 
18. da Fonseca, A.C.P., et al., Genetics of non-syndromic childhood obesity and the 
use of high-throughput DNA sequencing technologies. J Diabetes Complications, 
2017. 31(10): p. 1549-1561. 
19. Peeters, A., et al., Obesity in adulthood and its consequences for life expectancy: a 
life-table analysis. Ann Intern Med, 2003. 138(1): p. 24-32. 
20. Fontaine, K.R., et al., Years of life lost due to obesity. JAMA, 2003. 289(2): p. 
187-93. 
82 
 
21. Pi-Sunyer, F.X., The obesity epidemic: pathophysiology and consequences of 
obesity. Obes Res, 2002. 10 Suppl 2: p. 97S-104S. 
22. Dagenais, G.R., et al., Prognostic impact of body weight and abdominal obesity in 
women and men with cardiovascular disease. Am Heart J, 2005. 149(1): p. 54-60. 
23. Al Suwaidi, J., et al., Obesity is independently associated with coronary 
endothelial dysfunction in patients with normal or mildly diseased coronary 
arteries. J Am Coll Cardiol, 2001. 37(6): p. 1523-8. 
24. Gaudet, D., et al., Relationships of abdominal obesity and hyperinsulinemia to 
angiographically assessed coronary artery disease in men with known mutations 
in the LDL receptor gene. Circulation, 1998. 97(9): p. 871-7. 
25. Petrauskiene, V., et al., The risk of venous thromboembolism is markedly elevated 
in patients with diabetes. Diabetologia, 2005. 48(5): p. 1017-21. 
26. Goldhaber, S.Z., et al., A prospective study of risk factors for pulmonary embolism 
in women. JAMA, 1997. 277(8): p. 642-5. 
27. Deguchi, H., et al., High-density lipoprotein deficiency and dyslipoproteinemia 
associated with venous thrombosis in men. Circulation, 2005. 112(6): p. 893-9. 
28. Doggen, C.J., et al., Serum lipid levels and the risk of venous thrombosis. 
Arterioscler Thromb Vasc Biol, 2004. 24(10): p. 1970-5. 
29. Ageno, W., et al., The metabolic syndrome and the risk of venous thrombosis: a 
case-control study. J Thromb Haemost, 2006. 4(9): p. 1914-8. 
30. Cushman, M., et al., Deep vein thrombosis and pulmonary embolism in two 
cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med, 
2004. 117(1): p. 19-25. 
31. Prandoni, P., Venous and arterial thrombosis: Two aspects of the same disease? 
Clin Epidemiol, 2009. 1: p. 1-6. 
32. Ageno, W., et al., Cardiovascular risk factors and venous thromboembolism: a 
meta-analysis. Circulation, 2008. 117(1): p. 93-102. 
33. Ray, J.G., Dyslipidemia, statins, and venous thromboembolism: a potential risk 
factor and a potential treatment. Curr Opin Pulm Med, 2003. 9(5): p. 378-84. 
34. Sundell, I.B., et al., Fibrinolytic variables are related to age, sex, blood pressure, 
and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin 
Epidemiol, 1989. 42(8): p. 719-23. 
35. Landin, K., et al., Abdominal obesity is associated with an impaired fibrinolytic 
activity and elevated plasminogen activator inhibitor-1. Metabolism, 1990. 
39(10): p. 1044-8. 
36. Sakkinen, P.A., et al., Clustering of procoagulation, inflammation, and 
fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J 
Epidemiol, 2000. 152(10): p. 897-907. 
37. Englyst, N.A., et al., A novel role for CD36 in VLDL-enhanced platelet activation. 
Diabetes, 2003. 52(5): p. 1248-55. 
38. Michelson, A.D., How platelets work: platelet function and dysfunction. J Thromb 
Thrombolysis, 2003. 16(1-2): p. 7-12. 
39. Ruggeri, Z.M., Platelets in atherothrombosis. Nat Med, 2002. 8(11): p. 1227-34. 
40. Duke, W.W., The relation of blood platelets to hemorrhagic disease. By W.W. 
Duke. JAMA, 1983. 250(9): p. 1201-9. 
41. Born, G.V., Aggregation of blood platelets by adenosine diphosphate and its 
reversal. Nature, 1962. 194: p. 927-9. 
42. Paniccia, R., et al., Platelet function tests: a comparative review. Vasc Health 
Risk Manag, 2015. 11: p. 133-48. 
83 
 
43. Macfarlane, R.G., An Enzyme Cascade in the Blood Clotting Mechanism, and Its 
Function as a Biochemical Amplifier. Nature, 1964. 202: p. 498-9. 
44. Nair, S.C., et al., Tests of global haemostasis and their applications in bleeding 
disorders. Haemophilia, 2010. 16 Suppl 5: p. 85-92. 
45. Reiner, A.P., D.S. Siscovick, and F.R. Rosendaal, Hemostatic risk factors and 
arterial thrombotic disease. Thromb Haemost, 2001. 85(4): p. 584-95. 
46. Mertens, I. and L.F. Van Gaal, Obesity, haemostasis and the fibrinolytic system. 
Obes Rev, 2002. 3(2): p. 85-101. 
47. Hoffman, M. and D.M. Monroe, 3rd, The action of high-dose factor VIIa (FVIIa) 
in a cell-based model of hemostasis. Dis Mon, 2003. 49(1): p. 14-21. 
48. Loskutoff, D.J. and F. Samad, The adipocyte and hemostatic balance in obesity: 
studies of PAI-1. Arterioscler Thromb Vasc Biol, 1998. 18(1): p. 1-6. 
49. Rijken, D.C. and S. Uitte de Willige, Inhibition of Fibrinolysis by Coagulation 
Factor XIII. Biomed Res Int, 2017. 2017: p. 1209676. 
50. Lundgren, C.H., et al., Elaboration of type-1 plasminogen activator inhibitor from 
adipocytes. A potential pathogenetic link between obesity and cardiovascular 
disease. Circulation, 1996. 93(1): p. 106-10. 
51. Abdollahi, M., M. Cushman, and F.R. Rosendaal, Obesity: risk of venous 
thrombosis and the interaction with coagulation factor levels and oral 
contraceptive use. Thromb Haemost, 2003. 89(3): p. 493-8. 
52. Ilich, A., I. Bokarev, and N.S. Key, Global assays of fibrinolysis. Int J Lab 
Hematol, 2017. 39(5): p. 441-447. 
53. Hoffman, M. and D.M. Monroe, 3rd, A cell-based model of hemostasis. Thromb 
Haemost, 2001. 85(6): p. 958-65. 
54. Morel, O., et al., Cellular mechanisms underlying the formation of circulating 
microparticles. Arterioscler Thromb Vasc Biol, 2011. 31(1): p. 15-26. 
55. VanWijk, M.J., et al., Microparticles in cardiovascular diseases. Cardiovasc Res, 
2003. 59(2): p. 277-87. 
56. Bevers, E.M., et al., Generation of prothrombin-converting activity and the 
exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem, 
1982. 122(2): p. 429-36. 
57. Hugel, B., et al., Membrane microparticles: two sides of the coin. Physiology 
(Bethesda), 2005. 20: p. 22-7. 
58. Mause, S.F. and C. Weber, Microparticles: protagonists of a novel 
communication network for intercellular information exchange. Circ Res, 2010. 
107(9): p. 1047-57. 
59. Burger, D., et al., Microparticles: biomarkers and beyond. Clin Sci (Lond), 2013. 
124(7): p. 423-41. 
60. Varon, D. and E. Shai, Platelets and their microparticles as key players in 
pathophysiological responses. J Thromb Haemost, 2015. 13 Suppl 1: p. S40-6. 
61. Piccin, A., W.G. Murphy, and O.P. Smith, Circulating microparticles: 
pathophysiology and clinical implications. Blood Rev, 2007. 21(3): p. 157-71. 
62. van der Zee, P.M., et al., P-selectin- and CD63-exposing platelet microparticles 
reflect platelet activation in peripheral arterial disease and myocardial infarction. 
Clin Chem, 2006. 52(4): p. 657-64. 
63. Kreutz, R.P., et al., Morbid obesity and metabolic syndrome in Ossabaw 
miniature swine are associated with increased platelet reactivity. Diabetes Metab 
Syndr Obes, 2011. 4: p. 99-105. 
84 
 
64. Csongradi, E., et al., Increased levels of platelet activation markers are positively 
associated with carotid wall thickness and other atherosclerotic risk factors in 
obese patients. Thromb Haemost, 2011. 106(4): p. 683-92. 
65. Basili, S., et al., Insulin resistance as a determinant of platelet activation in obese 
women. J Am Coll Cardiol, 2006. 48(12): p. 2531-8. 
66. Hameed, A., et al., Levels of platelet-derived microparticles and soluble p-selectin 
in patients of acute myocardial infarction (case control study). J Pak Med Assoc, 
2017. 67(7): p. 998-1003. 
67. Hayward, C.P., Platelet activation in the pathogenesis of obesity and vascular 
disease. Thromb Haemost, 2011. 106(4): p. 567-8. 
68. Deng, F., S. Wang, and L. Zhang, Endothelial Microparticles Act as Novel 
Diagnostic and Therapeutic Biomarkers of Diabetes and Its Complications: A 
Literature Review. Biomed Res Int, 2016. 2016: p. 9802026. 
69. Mutin, M., F. Dignat-George, and J. Sampol, Immunologic phenotype of cultured 
endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens, 
1997. 50(5): p. 449-58. 
70. Jimenez, J.J., et al., Endothelial cells release phenotypically and quantitatively 
distinct microparticles in activation and apoptosis. Thromb Res, 2003. 109(4): p. 
175-80. 
71. Leroyer, A.S., et al., Endothelial-derived microparticles: Biological conveyors at 
the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost, 
2010. 104(3): p. 456-63. 
72. Yun, C.H., et al., Increased circulating endothelial microparticles and carotid 
atherosclerosis in obstructive sleep apnea. J Clin Neurol, 2010. 6(2): p. 89-98. 
73. Li, M., et al., Tobacco smoke induces the generation of procoagulant 
microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc 
Biol, 2010. 30(9): p. 1818-24. 
74. Trzepizur, W., et al., Nocturnal release of leukocyte-derived microparticles in 
males with obstructive sleep apnoea. Eur Respir J, 2011. 37(5): p. 1293-5. 
75. Angelillo-Scherrer, A., Leukocyte-derived microparticles in vascular homeostasis. 
Circ Res, 2012. 110(2): p. 356-69. 
76. Mackman, N., R.E. Tilley, and N.S. Key, Role of the extrinsic pathway of blood 
coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol, 2007. 
27(8): p. 1687-93. 
77. Owens, A.P., 3rd and N. Mackman, Microparticles in hemostasis and thrombosis. 
Circ Res, 2011. 108(10): p. 1284-97. 
78. Alkhatatbeh, M.J., et al., The putative diabetic plasma marker, soluble CD36, is 
non-cleaved, non-soluble and entirely associated with microparticles. J Thromb 
Haemost, 2011. 9(4): p. 844-51. 
79. Alkhatatbeh, M.J., et al., The origin of circulating CD36 in type 2 diabetes. Nutr 
Diabetes, 2013. 3: p. e59. 
80. van Veen, J.J., A. Gatt, and M. Makris, Thrombin generation testing in routine 
clinical practice: are we there yet? Br J Haematol, 2008. 142(6): p. 889-903. 
81. Hemker, H.C., et al., The calibrated automated thrombogram (CAT): a universal 
routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb, 
2002. 32(5-6): p. 249-53. 
82. Beijers, H.J., et al., Body composition as determinant of thrombin generation in 
plasma: the Hoorn study. Arterioscler Thromb Vasc Biol, 2010. 30(12): p. 2639-
47. 
85 
 
83. Ay, L., et al., Thrombin generation in morbid obesity: significant reduction after 
weight loss. J Thromb Haemost, 2010. 8(4): p. 759-65. 
84. Luddington, R.J., Thrombelastography/thromboelastometry. Clin Lab Haematol, 
2005. 27(2): p. 81-90. 
85. Spiezia, L., et al., Whole blood coagulation assessment using rotation 
thrombelastogram thromboelastometry in patients with acute deep vein 
thrombosis. Blood Coagul Fibrinolysis, 2008. 19(5): p. 355-60. 
86. Born, G.V. and M.J. Cross, Effect of adenosine diphosphate on the concentration 
of platelets in circulating blood. Nature, 1963. 197: p. 974-6. 
87. Cardinal, D.C. and R.J. Flower, The electronic aggregometer: a novel device for 
assessing platelet behavior in blood. J Pharmacol Methods, 1980. 3(2): p. 135-58. 
88. Toth, O., et al., Multiple electrode aggregometry: a new device to measure 
platelet aggregation in whole blood. Thromb Haemost, 2006. 96(6): p. 781-8. 
89. Breet, N.J., et al., Comparison of platelet function tests in predicting clinical 
outcome in patients undergoing coronary stent implantation. JAMA, 2010. 
303(8): p. 754-62. 
90. Fain, J.N., et al., Comparison of the release of adipokines by adipose tissue, 
adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal 
adipose tissues of obese humans. Endocrinology, 2004. 145(5): p. 2273-82. 
91. Stolarczyk, E., Adipose tissue inflammation in obesity: a metabolic or immune 
response? Curr Opin Pharmacol, 2017. 37: p. 35-40. 
92. Flier, J.S., Obesity wars: molecular progress confronts an expanding epidemic. 
Cell, 2004. 116(2): p. 337-50. 
93. Farooqi, I.S., et al., Clinical and molecular genetic spectrum of congenital 
deficiency of the leptin receptor. N Engl J Med, 2007. 356(3): p. 237-47. 
94. Ahima, R.S. and J.S. Flier, Leptin. Annu Rev Physiol, 2000. 62: p. 413-37. 
95. Konstantinides, S., et al., Leptin-dependent platelet aggregation and arterial 
thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin 
Invest, 2001. 108(10): p. 1533-40. 
96. Corsonello, A., et al., Leptin-dependent platelet aggregation in healthy, 
overweight and obese subjects. Int J Obes Relat Metab Disord, 2003. 27(5): p. 
566-73. 
97. Ruan, H. and H.F. Lodish, Insulin resistance in adipose tissue: direct and indirect 
effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev, 2003. 14(5): 
p. 447-55. 
98. Ruan, H., et al., Profiling gene transcription in vivo reveals adipose tissue as an 
immediate target of tumor necrosis factor-alpha: implications for insulin 
resistance. Diabetes, 2002. 51(11): p. 3176-88. 
99. Yoshinaga, R., et al., High-sensitivity C reactive protein as a predictor of 
inhospital mortality in patients with cardiovascular disease at an emergency 
department: a retrospective cohort study. BMJ Open, 2017. 7(10): p. e015112. 
100. Corbalan, M.D., et al., Effectiveness of cognitive-behavioral therapy based on the 
Mediterranean diet for the treatment of obesity. Nutrition, 2009. 25(7-8): p. 861-9. 
101. Jensen, M.D., et al., 2013 AHA/ACC/TOS guideline for the management of 
overweight and obesity in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines and 
The Obesity Society. J Am Coll Cardiol, 2014. 63(25 Pt B): p. 2985-3023. 
102. Hess, D.S. and D.W. Hess, Biliopancreatic diversion with a duodenal switch. 
Obes Surg, 1998. 8(3): p. 267-82. 
86 
 
103. Matthews, D.R., et al., Homeostasis model assessment: insulin resistance and 
beta-cell function from fasting plasma glucose and insulin concentrations in man. 
Diabetologia, 1985. 28(7): p. 412-9. 
104. Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in, 
Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High 
Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001. 285(19): 
p. 2486-97. 
105. Koutroumpi, S., et al., Thrombin generation in Cushing's Syndrome: do the 
conventional clotting indices tell the whole truth? Pituitary, 2014. 17(1): p. 68-75. 
106. Lacroix, R., et al., Standardization of platelet-derived microparticle enumeration 
by flow cytometry with calibrated beads: results of the International Society on 
Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost, 
2010. 8(11): p. 2571-4. 
107. Campello, E., et al., Evaluation of a procoagulant phospholipid functional assay 
as a routine test for measuring circulating microparticle activity. Blood Coagul 
Fibrinolysis, 2014. 25(5): p. 534-7. 
108. Ten Cate, H., Thrombin generation in clinical conditions. Thromb Res, 2012. 
129(3): p. 367-70. 
109. Santilli, F., et al., Platelet activation in obesity and metabolic syndrome. Obes 
Rev, 2012. 13(1): p. 27-42. 
110. Bordeaux, B.C., et al., Effect of obesity on platelet reactivity and response to low-
dose aspirin. Prev Cardiol, 2010. 13(2): p. 56-62. 
111. Darvall, K.A., et al., Obesity and thrombosis. Eur J Vasc Endovasc Surg, 2007. 
33(2): p. 223-33. 
112. Rosito, G.A., et al., Association between obesity and a prothrombotic state: the 
Framingham Offspring Study. Thromb Haemost, 2004. 91(4): p. 683-9. 
113. Morel, O., et al., Short-term very low-calorie diet in obese females improves the 
haemostatic balance through the reduction of leptin levels, PAI-1 concentrations 
and a diminished release of platelet and leukocyte-derived microparticles. Int J 
Obes (Lond), 2011. 35(12): p. 1479-86. 
114. Taura, P., et al., Clinical markers of the hypercoagulable state by rotational 
thrombelastometry in obese patients submitted to bariatric surgery. Surg Endosc, 
2014. 28(2): p. 543-51. 
115. Haas, T., et al., Comparison of thromboelastometry (ROTEM(R)) with standard 
plasmatic coagulation testing in paediatric surgery. Br J Anaesth, 2012. 108(1): 
p. 36-41. 
116. Schaden, E., et al., Fibrinogen function after severe burn injury. Burns, 2012. 
38(1): p. 77-82. 
117. Kozek-Langenecker, S.A., Perioperative coagulation monitoring. Best Pract Res 
Clin Anaesthesiol, 2010. 24(1): p. 27-40. 
118. Solomon, C., et al., A comparison of fibrinogen measurement methods with fibrin 
clot elasticity assessed by thromboelastometry, before and after administration of 
fibrinogen concentrate in cardiac surgery patients. Transfusion, 2011. 51(8): p. 
1695-706. 
119. Helal, O., et al., Increased levels of microparticles originating from endothelial 
cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship 
with oxidative stress. Nutr Metab Cardiovasc Dis, 2011. 21(9): p. 665-71. 
87 
 
120. Zhang, X., et al., Platelet-derived microparticle count and surface molecule 
expression differ between subjects with and without type 2 diabetes, independently 
of obesity status. J Thromb Thrombolysis, 2014. 37(4): p. 455-63. 
121. Stepanian, A., et al., Microparticle increase in severe obesity: not related to 
metabolic syndrome and unchanged after massive weight loss. Obesity (Silver 
Spring), 2013. 21(11): p. 2236-43. 
122. Gregor, M.F. and G.S. Hotamisligil, Inflammatory mechanisms in obesity. Annu 
Rev Immunol, 2011. 29: p. 415-45. 
123. Tian, Y.F., et al., Leptin-mediated inflammatory signaling crucially links visceral 
fat inflammation to obesity-associated beta-cell dysfunction. Life Sci, 2014. 
116(1): p. 51-8. 
124. Murakami, T., et al., Impact of weight reduction on production of platelet-derived 
microparticles and fibrinolytic parameters in obesity. Thromb Res, 2007. 119(1): 
p. 45-53. 
125. Cheng, V., et al., Restoration of glycemic control in patients with type 2 diabetes 
mellitus after bariatric surgery is associated with reduction in microparticles. 
Surg Obes Relat Dis, 2013. 9(2): p. 207-12. 
126. Thorne, R.F., et al., CD36 is a receptor for oxidized high density lipoprotein: 
implications for the development of atherosclerosis. FEBS Lett, 2007. 581(6): p. 
1227-32. 
127. Sanchez, C., et al., Diet modulates endogenous thrombin generation, a biological 
estimate of thrombosis risk, independently of the metabolic status. Arterioscler 
Thromb Vasc Biol, 2012. 32(10): p. 2394-404. 
128. Lacroix, R., et al., Standardization of pre-analytical variables in plasma 
microparticle determination: results of the International Society on Thrombosis 
and Haemostasis SSC Collaborative workshop. J Thromb Haemost, 2013. 
129. Gheldof, D., et al., Thrombin generation assay and transmission electron 
microscopy: a useful combination to study tissue factor-bearing microvesicles. J 
Extracell Vesicles, 2013. 2. 
130. Connor, D.E., et al., The majority of circulating platelet-derived microparticles 
fail to bind annexin V, lack phospholipid-dependent procoagulant activity and 
demonstrate greater expression of glycoprotein Ib. Thromb Haemost, 2010. 
103(5): p. 1044-52. 
131. Shantsila, E., et al., Circulating microparticles: challenges and perspectives of 
flow cytometric assessment. Thromb Haemost, 2014. 111(6): p. 1009-14. 
132. Arraud, N., et al., Fluorescence triggering: A general strategy for enumerating 
and phenotyping extracellular vesicles by flow cytometry. Cytometry A, 2016. 
89(2): p. 184-95. 
133. Lacroix, R., et al., Revisited role of microparticles in arterial and venous 
thrombosis. J Thromb Haemost, 2013. 11 Suppl 1: p. 24-35. 
 
Monographs 
M1. P. Prandoni Il tromboembolismo venoso: attualità e prospettive. Piccin Editore, 
Padova 2008. 
M2. Standard Italiani per la Cura dell’Obesità. SIO/ADI. 2012/2013.  
 
